

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxml624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:32:15 ON 13 APR 2008

=> fil reg
COST IN U.S. DOLLARS
SINCE FILE
ENTRY
SESSION
0.21
0.21
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:32:30 ON 13 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 APR 2008 HIGHEST RN 1013911-12-0
DICTIONARY FILE UPDATES: 11 APR 2008 HIGHEST RN 1013911-12-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\1059788.str





```
chain nodes :
11 12 21 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 15 16 17 18 19 20
ring/chain nodes :
10
chain bonds :
4-10 5-21 6-12 7-15 8-11 22-23 23-24
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 15-16 15-20 16-17 17-18 18-19
19-20
exact/norm bonds :
1-2 1-6 2-3 3-4 3-9 4-5 4-10 5-6 5-21 6-12 8-9 8-11 22-23
exact bonds :
2-7 7-8 7-15 23-24
normalized bonds :
15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 : 15 :
```

G1:H,CH3

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:CLASS
22:CLASS 23:CLASS 24:CLASS 27:Atom
```

L1 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\1059788.str



chain nodes :

11 12 21 22 23 24

ring nodes :

1 2 3 4 5 6 7 8 9 15 16 17 18 19 20

ring/chain nodes :

10

chain bonds :

4-10 5-21 6-12 7-15 8-11 22-23 23-24

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 15-16 15-20 16-17 17-18 18-19
19-20

exact/norm bonds :

1-2 1-6 2-3 3-4 3-9 4-5 4-10 5-6 5-21 6-12 8-9 8-11 22-23

exact bonds :

2-7 7-8 7-15 23-24

normalized bonds :

15-16 15-20 16-17 17-18 18-19 19-20

isolated ring systems :

containing 1 : 15 :

G1:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:CLASS
22:CLASS 23:CLASS 24:CLASS 27:Atom

L2 STRUCTURE UPLOADED

=> d 12
L2 HAS NO ANSWERS
L2 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 12 sam
SAMPLE SEARCH INITIATED 16:33:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 649 TO ITERATE

100.0% PROCESSED 649 ITERATIONS 30 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11452 TO 14508
PROJECTED ANSWERS: 272 TO 928

L3 30 SEA SSS SAM L2

=> s 12 ful
FULL SEARCH INITIATED 16:33:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 13371 TO ITERATE

100.0% PROCESSED 13371 ITERATIONS 786 ANSWERS
SEARCH TIME: 00.00.01

L4 786 SEA SSS FUL L2

=> fil cap1
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 16:33:33 ON 13 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2008 VOL 148 ISS 16
FILE LAST UPDATED: 11 Apr 2008 (20080411/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 14
L5 30 L4

=> d 15 ibib hitstr abs 1-30

LS ANSWER 1 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1476389 CAPLUS
 DOCUMENT NUMBER: 148:253971
 TITLE: MPZP: A novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist
 AUTHOR(S): Richardson, Heather N.; Zhao, Yu; Fekete, Eva M.; Funk, Cindy K.; Wirsching, Peter; Janda, Kim D.; Zorrilla, Eric P.; Koob, George F.
 CORPORATE SOURCE: Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, 92037, USA
 SOURCE: Pharmacology, Biochemistry and Behavior (2008), 88(4), 497-510
 CODEN: PBBHAU; ISSN: 0091-3057
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-76-8, MPZP
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (MPZP: CRF1 receptor antagonist)
 RN 202579-76-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB The extrahypothalamic stress peptide corticotropin-releasing factor (CRF) system is an important regulator of behavioral responses to stress. Dysregulation of CRF and the CRF type 1 receptor (CRF1) system is hypothesized to underlie many stress-related disorders. Modulation of the CRF1 system by non-peptide antagonists currently is being explored as a therapeutic approach for anxiety disorders and alc. dependence. Here, we describe a new, less hydrophilic ($c\log P$ apprx. 2.95), small mol., non-peptide CRF1 antagonist with high affinity ($K_i = 4.9 \text{ nM}$) and specificity for CRF1 receptors: N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-amine (MPZP). The compound was systemically administered to adult male rats in two behavioral models dependent on the CRF1 system: defensive burying (0, 5, 20 mg/kg, $n = 6-11$ for each dose) and alc. dependence (0, 5, 10, 20 mg/kg, $n = 8$ for each self-administration group). Acute administration of MPZP reduced burying behavior in the defensive burying model of active anxiety-like behavior. MPZP also attenuated withdrawal-induced excessive drinking in the self-administration model of alc. dependence without affecting nondependent alc. drinking or water consumption. The present findings support the proposed significance of the CRF1 system in anxiety and alc. dependence and introduce a promising new compound for further development in the treatment of alc. dependence and stress-related disorders.

REFERENCE COUNT: 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 2 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 20071364083 CAPLUS
 DOCUMENT NUMBER: 148:1117
 TITLE: Melatonin agonist for treatment of depressive disorders
 INVENTOR(S): Wolfgang, Curt D.; Polymeropoulos, Michael H.
 PATENT ASSIGNEE(S): Vanda Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 24pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2007137227 | A1 | 20071129 | WO 2007-US69373 | 20070521 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,
GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,
KN, KE, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: US 2006-747861P P 20060522
 IT 202579-74-6, DMP904 202579-74-6D, DMP904, metabolites
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (melatonin agonist for treatment of depressive disorders)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-
 methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-
 methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB A method of treating depression comprising administering a melatonin agonist.

ACCESSION NUMBER: 2007:409409 CAPLUS

DOCUMENT NUMBER: 146:428737

TITLE: Pyrazolo[1,5-a]pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

INVENTOR(S): Hossner, Frank

PATENT ASSIGNEE(S): Sb Pharmco Puerto Rico Inc, P. R.; Neurocrine Biosciences Inc

SOURCE: PCT Int. Appl., 37pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2007039264 | A1 | 20070412 | WO 2006-EP9531 | 20060928 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

| | | | | |
|---------------|----|----------|-----------------|----------|
| WO 2006044958 | A1 | 20060427 | WO 2005-US37576 | 20051019 |
|---------------|----|----------|-----------------|----------|

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

| | | |
|------------------------|-----------------|------------|
| PRIORITY APPLN. INFO.: | GB 2005-19957 | A 20050930 |
| | WO 2005-US37576 | A 20051019 |
| | US 2004-620060P | P 20041019 |


IT 885220-61-1P

RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of polymorphic form of pyrazolopyrimidinyl derivative and its composition useful as CRF receptor antagonist)

RN 885220-61-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 885220-98-4P 885220-99-5P 885221-20-5P

933770-76-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of polymorphic form of pyrazolopyrimidinyl derivative and its composition useful as CRF receptor antagonist)

RN 885220-98-4 CAPLUS

CN Butanoic acid, 2-[(3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, (1-iminoethyl)azanyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 885220-99-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 885220-61-1

CMF C22 H26 N6 O2

Absolute stereochemistry.




CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 885221-20-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, hydrochloride (1:?) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 933770-76-4 CAPLUS
CN Butanoic acid, 2-[(3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



AB The present invention generally relates to the polymorph Form 2 of [3-(4-methoxy-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)-propyl]-amine (I), useful as a CRF receptor antagonist. The present invention also relates to pharmaceutical compns. comprising the same and methods of using the same. Thus, 0.74 g of compound I polymorph Form 1 (preparation given) was slurried in 50% aqueous isopropanol at a temperature cycled between 0 and 40° for 24 h, at ambient temperature for 3 days, and at the temperature cycled between 0 to 40° for 24 h, and the residue was filtered off and dried to give 0.70 g of compound I Form 2. Granules were prepared containing compound I polymorph


Form 2

200.0%, HPMC 46.88%, sodium lauryl sulfate 3.13%, sodium croscarmellose 9.38%, and mannitol 53.11%. Coated tablets were then formulated comprising (i) cores containing 83.33% granules obtained, Avicel PH 102 12.67, sodium croscarmellose 3.0%, and magnesium stearate 1.0%, and (ii) coating of Opadry OY-S-28876 3.0%.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 4 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:173880 CAPLUS
 DOCUMENT NUMBER: 146:229377
 TITLE: Preparation of pyrazolo[1,5-a]pyrimidines as
 anticancer drugs.
 INVENTOR(S): Murphy, Finbarr; James, Theo Richard; Hayes, Ian
 PATENT ASSIGNEE(S): Eirix Therapeutics Limited, Ire.
 SOURCE: PCT Int. Appl., 91pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|-------------------|--------------|----------------------------------|--------------------------|
| WO 2007017678 | A1 | 20070215 | WO 2006-GB2968 | 20060808 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JE, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GE, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| PRIORITY APPLN. INFO.: | | | GB 2005-16378
US 2005-706593P | A 20050809
P 20050809 |
| OTHER SOURCE(S): | MARPAT 146:229377 | | | |
| IT 924902-14-7P | 924902-16-9P | 924902-18-1P | | |
| 924902-19-2P | | | | |
| RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses) | | | | |
| (claimed compound; preparation of pyrazolopyrimidines as anticancer drugs) | | | | |
| RN 924902-14-7 CAPLUS | | | | |
| CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-methoxyphenyl)-N-(2-
pyridinylmethyl)- (CA INDEX NAME) | | | | |




RN 924902-16-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3, 4-dimethoxyphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 924902-18-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxyphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 924902-19-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2, 4-dimethoxyphenyl)-N-(2-pyridinylmethyl)- (CA INDEX NAME)



GI



I

AB Title compds. [I; Cyl = (substituted) 5-10 membered mono- or bicyclic (hetero)aryl; R1-R3 = H, OH, halo, (substituted) alkyl, haloalkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, cyano, 5-6 membered heteroaryl, NO₂, amino, cyano, etc.; R4 = NHCy2; Cy2 = (substituted) cyclic group], were prepared Thus, 7-chloro-3-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine (preparation given), 2-picolyamine, and diisopropylethylamine were heated in Me₂CHOH at 85° for 45 min. to give [3-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]pyridin-2-ylmethylamine. The latter at 10 μM gave a 68% kill of MCF7 cells.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:382981 CAPLUS

DOCUMENT NUMBER: 144:432830

TITLE: Preparation of pyrazolo[1,5-a]pyrimidines as corticotropin-releasing factor (CRF) receptor antagonists.

INVENTOR(S): Lanier, Marion; Luo, Zhiyong; Moorjani, Manisha; Tellew, John Edward; Williams, John F.; Zhang, Xiaohu

PATENT ASSIGNEE(S): Sb Pharmco Puerto Rico Inc., P. R.; Neurocrine Biosciences Inc.

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2006044958 | A1 | 20060427 | WO 2005-US37576 | 20051019 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2005295353 | A1 | 20060427 | AU 2005-295353 | 20051019 |
| CA 2584567 | A1 | 20060427 | CA 2005-2584567 | 20051019 |
| EP 1802627 | A1 | 20070704 | EP 2005-818308 | 20051019 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR | | | | |
| CN 101084219 | A | 20071205 | CN 2005-80043716 | 20051019 |
| WO 2007039264 | A1 | 20070412 | WO 2006-EP9531 | 20060928 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| IN 2007DN02733 | A | 20070803 | IN 2007-DN2733 | 20070412 |
| MX 200704701 | A | 20070614 | MX 2007-4701 | 20070418 |
| KR 2007088621 | A | 20070829 | KR 2007-708794 | 20070418 |
| NO 2007002541 | A | 20070625 | NO 2007-2541 | 20070516 |
| PRIORITY APPLN. INFO.: | | | US 2004-620060P | P 20040109 |
| | | | GB 2005-19957 | A 20050930 |
| | | | WO 2005-US37576 | W 20051019 |

OTHER SOURCE(S): MARPAT 144:432830


IT 885220-17-7P 885220-18-8P 885220-19-9P
 885220-20-2P 885220-21-3P 885220-22-4P
 885220-23-5P 885220-24-6P 885220-25-7P
 885220-26-8P 885220-27-9P 885220-28-0P
 885220-29-1P 885220-30-4P 885220-31-5P
 885220-32-6P 885220-34-8P 885220-35-9P
 885220-36-0P 885220-37-1P 885220-38-2P
 885220-41-7P 885220-42-8P 885220-43-9P
 885220-44-0P 885220-45-1P 885220-46-2P
 885220-47-3P 885220-48-4P 885220-49-5P
 885220-50-8P 885220-51-9P 885220-52-0P
 885220-53-1P 885220-54-2P 885220-55-3P
 885220-56-4P 885220-57-5P 885220-58-6P
 885220-59-7P 885220-60-0P 885220-61-1P
 885220-62-2P 885220-63-3P 885220-64-4P
 885220-65-5P 885220-68-8P 885220-69-9P
 885220-70-2P 885220-71-3P 885220-72-4P
 885220-73-5P 885220-74-6P 885220-75-7P
 885220-76-8P 885220-77-9P 885220-78-0P
 885220-79-1P 885220-80-4P 885220-81-5P
 885220-82-6P 885220-83-7P 885220-84-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 885220-17-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 885220-18-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]propyl]- (CA INDEX NAME)




RN 885220-19-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)-2-phenylethyl]- (CA INDEX NAME)




RN 885220-20-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (CA INDEX NAME)




RN 885220-21-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)




RN 885220-22-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 885220-23-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[{3-(1-methylethyl)-1,2,4-oxadiazol-5-yl}methyl]- (CA INDEX NAME)



RN 885220-24-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1R)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-25-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-26-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]propyl)- (CA INDEX NAME)




RN 885220-27-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 885220-28-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)cyclopropyl]- (CA INDEX NAME)




RN 885220-29-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(3-ethyl-1,2,4-oxadiazol-5-yl)cyclopropyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 885220-30-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[3-propyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)



RN 885220-31-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]cyclopropyl]- (CA INDEX NAME)



RN 885220-32-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1R)-2-(3-ethyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-34-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-7-[(2S)-2-(3-methyl-1,2,4-oxadiazol-5-yl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-35-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)




RN 885220-36-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (CA INDEX NAME)




RN 885220-37-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-(3-methylbutyl)-] (CA INDEX NAME)




RN 885220-38-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[3-methyl-1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (CA INDEX NAME)




RN 885220-41-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)




RN 885220-42-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (CA INDEX NAME)




RN 885220-43-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 885220-44-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[2,2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]- (CA INDEX NAME)




RN 885220-45-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 885220-46-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]ethyl]-
(CA INDEX NAME)



RN 885220-47-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-
(CA INDEX NAME)


Absolute stereochemistry.



RN 885220-48-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-methyl-2-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 885220-49-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-methyl-2-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 885220-50-8 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]propyl]- (CA INDEX NAME)



RN 885220-51-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-[(3-cyclopropyl-1,2,4-oxadiazol-5-yl)methyl]propyl]-3-(2,4-dimethoxyphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 885220-52-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]propyl]- (CA INDEX NAME)



RN 885220-53-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 885220-54-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl)- (CA INDEX NAME)



RN 885220-55-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[(1S)-2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-56-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-57-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-58-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-59-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-60-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)methyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-61-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-62-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-63-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-7-[(2S)-2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-64-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-65-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)




RN 885220-68-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-ethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)



RN 885220-69-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-[3-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)



RN 885220-70-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-71-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-72-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-73-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1R)-2-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-1-methylethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methyl-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-76-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2-trifluoro-1-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-77-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)




RN 885220-78-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-7-[2-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-1-piperidinyl]- (CA INDEX NAME)




RN 885220-79-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(1,3,4-oxadiazol-2-yl)propyl]- (CA INDEX NAME)




RN 885220-80-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(5-methyl-1,3,4-oxadiazol-2-yl)propyl]- (CA INDEX NAME)



RN 885220-81-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]- (CA INDEX NAME)




RN 885220-82-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-methyl-2-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]ethyl]- (CA INDEX NAME)




RN 885220-83-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)



RN 885220-84-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-chloro-2-methoxyphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)




IT 885221-15-8P 885221-17-0P 885221-18-1P
885221-19-2P 885221-20-5P 885221-21-6P
885221-22-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 885221-15-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[1-(3-methyl-1,2,4-oxadiazol-5-yl)ethyl]- (CA INDEX NAME)



RN 885221-17-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N,2,5-trimethyl-N-(3-methyl-1,2,4-oxadiazol-5-yl)methyl]- (CA INDEX NAME)



RN 885221-18-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-19-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)butyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 885221-20-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 885221-21-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2,2-trifluoro-1-[(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)methyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-22-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-2,2-trifluoro-1-[(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)methyl]ethyl]-, hydrochloride (1:?) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


IT 885220-94-0P 885220-95-1P 885220-96-2P
 885220-97-3P 885220-98-4P 885220-99-5P
 885221-01-2P 885221-02-3P 885221-03-4P
 885221-04-5P 885221-05-6P 885221-06-7P
 885221-07-8P 885221-08-9P 885221-09-0P
 885221-10-3P 885221-11-4P 885221-12-5P
 885221-13-6P 885221-14-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 885220-94-0 CAPLUS

CN Butanoic acid, 2-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino-, methyl ester (CA INDEX NAME)



RN 885220-95-1 CAPLUS


CN Butanoic acid, 3-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, ethyl ester (CA INDEX NAME)



RN 885220-96-2 CAPLUS

CN L-Norvaline, N-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 885220-97-3 CAPLUS


CN L-Norvaline, N-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 885220-98-4 CAPLUS
 CN Butanoic acid, 2-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino-, (1-iminoethyl)azanyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885220-99-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 885220-61-1
 CMF C22 H26 N6 O2

Absolute stereochemistry.




CM 2

CRN 75-75-2
CMF C H 4 O 3 S




RN 885221-01-2 CAPLUS
CN Glycine, N-[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(2-methoxyethyl)-, methyl ester (CA INDEX NAME)



RN 885221-02-3 CAPLUS
CN Butanenitrile, 3-[(3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-03-4 CAPLUS

CN Butanoic acid, 4,4,4-trifluoro-3-[(3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, ethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885221-04-5 CAPLUS


CN Butanoic acid, 4,4,4-trifluoro-3-[(3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885221-05-6 CAPLUS
CN Butanamide, 4,4,4-trifluoro-3-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 885221-06-7 CAPLUS
CN Butanenitrile, 4,4,4-trifluoro-3-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 885221-07-8 CAPLUS
CN Glycine, N-ethyl-N-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, methyl ester (CA INDEX NAME)




RN 885221-08-9 CAPLUS
CN Butanoic acid, 2-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino-, hydrazide (CA INDEX NAME)



RN 885221-09-0 CAPLUS
CN Butanoic acid, 2-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino-, 2-formylhydrazide (CA INDEX NAME)




RN 885221-10-3 CAPLUS
CN Butanoic acid, 2-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino-, 2-acetylhydrazide (CA INDEX NAME)




RN 885221-11-4 CAPLUS
CN Butaneperoxoic acid, 3-[3-(4-methoxy-2-methylphenyl)-2,5-

dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester (CA INDEX NAME)




RN 885221-12-5 CAPLUS

CN Butanoic acid, 3-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, hydrazide (CA INDEX NAME)




RN 885221-13-6 CAPLUS

CN Butanoic acid, 3-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, 2-acetylhydrazide (CA INDEX NAME)




RN 885221-14-7 CAPLUS

CN Butanoic acid, 2-[3-(2-chloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]-, methyl ester (CA INDEX NAME)



GI



AB Title compds. [I; R1 = H, (substituted) alkyl, haloalkyl, alkoxyalkyl, aralkyl, heterocycloalkyl; R2a, R2b = H, (substituted) alkyl, haloalkyl, aralkyl, alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl; R1R2a, R1R2b = atoms to form 4-7 membered ring; Y = bond, C(R4aR4b)m; m = 1, 2; R4a, R4b = H, (substituted) alkyl, aralkyl, alkoxyalkyl, alkylsulfonylalkyl, aminoalkyl; R4aR4bC = atoms to form a 3-7 membered ring; Het = (substituted) oxadiazolyl; n = 0-3; R6 = H, (substituted) alkyl; R7 = H, (substituted) alkyl, alkoxy, amino, alkylsulfonyl; p = 0-3; Ar = Ph, pyridyl], were prepared. Thus, [3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-[(S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]amine (multistep preparation given) showed CRF receptor binding affinity with Ki <100 nM.

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:962100 CAPLUS

DOCUMENT NUMBER: 143:266943

TITLE: CRF receptor antagonists, their preparations, their pharmaceutical composition and their uses

INVENTOR(S): Sree, Deborah; Grigoriadis, Dimitri; Williams, John
PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.; Glaxo Group Limited

SOURCE: PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 2005079868 | A2 | 20050901 | WO 2005-GB432 | 20050209 |
| WO 2005079868 | A3 | 20060126 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| EP 1722826 | A2 | 20061122 | EP 2005-708257 | 20050209 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FE, GB, GR, HU, IE,
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV | | | | |
| JP 2008053444 | T | 20080207 | JP 2006-552678 | 20050209 |
| US 20070129382 | A1 | 20070607 | US 2006-597788 | 20060808 |
| PRIORITY APPLN. INFO.: | | | US 2004-544758P | P 20040213 |
| | | | WO 2005-GB432 | W 20050209 |

OTHER SOURCE(S): CASREACT 143:266943

IT 863550-35-0P 863550-36-1P 863550-37-2P


863550-39-4P 863550-40-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrazolopyrimidine derivs. as CRF receptor antagonists)

RN 863550-35-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)



RN 863550-36-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-[2-methoxy-4-(methoxy-11C)phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 863550-37-2 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-ethyl-N-(2-fluoro-18F)ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 863550-39-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine, 3-(2,4-dimethoxyphenyl)-7-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 863550-40-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-ethyl-N-(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



GI




I

AB CRF receptor antagonists 2,5-dimethyl-3-(2,4-dimethoxyphenyl)-7-(diethylamino)pyrazolo[2,3-a]pyrimidine (I), 2,5-dimethyl-3-(2,4-dimethoxyphenyl)-7-(N-ethyl-N-methoxyethylamino)pyrazolo[2,3-a]pyrimidine, 2,5-dimethyl-3-(2,4-dimethoxyphenyl)-7-(2-(S)-methoxymethylpyrrolidinyl)pyrazolo[2,3-a]pyrimidine, and 2,5-dimethyl-3-(2,4-dimethoxyphenyl)-7-[N-ethyl-N-(2-fluoroethyl)amino]pyrazolo[2,3-a]pyrimidine were prepared and have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals. CRF receptor antagonists which are labeled with a positron emitting isotope for use in PET are also prepared. Thus, I was prepared in 7 steps starting from 3,4-dimethoxybenzaldehyde.


LS ANSWER 7 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:962049 CAPLUS
 DOCUMENT NUMBER: 143:254020
 TITLE: Therapeutic combinations of atypical antipsychotics
 with corticotropin releasing factor antagonists
 INVENTOR(S): Romano, Steven Joseph
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|--|----------|
| WO 2005079807 | A1 | 20050901 | WO 2005-IB251 | 20050201 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| AU 2005215257 | A1 | 20050901 | AU 2005-215257 | 20050201 |
| CA 2556160 | A1 | 20050901 | CA 2005-2556160 | 20050201 |
| EP 1718311 | A1 | 20061108 | EP 2005-702400 | 20050201 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
CN 1917882 A 20070221 CN 2005-80004943 20050201
BR 2005007609 A 20070703 BR 2005-7609 20050201
JP 2007522200 T 20070809 JP 2006-552710 20050201
US 20050209250 A1 20050922 US 2005-58329 20050214
IN 2006DN04617 A 20070810 IN 2006-DN4617 20060810
MX 2006PA09271 A 20061207 MX 2006-PA9271 20060814
NO 2006004054 A 20061110 NO 2006-4054 20060908 | | | | |
| PRIORITY APPLN. INFO.: | | | US 2004-544731P P 20040213
WO 2005-IB251 W 20050201 | |

OTHER SOURCE(S): MARPAT 143:254020
 IT 195054-99-0 202579-86-0
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic combinations of atypical antipsychotics with corticotropin
 releasing factor antagonists)
 RN 195054-99-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-
 methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



RN 202579-86-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB The present invention is directed to a pharmaceutical compns. for treating, for example, mood disorders or conditions, psychotic disorders or conditions, or a combination thereof, in a mammal such as a human, the composition comprising (a) an atypical antipsychotic, a prodrug thereof or a pharmaceutically acceptable salt of the atypical antipsychotic or prodrug thereof, (b) a corticotropin releasing factor antagonist, a prodrug thereof, or pharmaceutically acceptable salt of said corticotropin releasing factor antagonist or prodrug thereof, and optionally (c) a pharmaceutically acceptable vehicle, carrier or diluent. A pharmaceutical composition is prepared containing ziprasidone with a corticotropin releasing factor antagonist such a 4-(1-ethylproppoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)pyridine.


REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 8 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:612294 CAPLUS
 DOCUMENT NUMBER: 143:133390
 TITLE: Preparation of pyrazolopyrimidines as CRF receptor antagonists
 INVENTOR(S): Luo, Zhiyong; Skee, Deborah; Tellew, John Edward;
 Williams, John; Zhang, Xiahou
 PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.
 SOURCE: PCT Int. Appl., 79 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 2005063756 | A1 | 20050714 | WO 2004-IB4293 | 20041220 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| EP 1697369 | A1 | 20060906 | EP 2004-806458 | 20041220 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS | | | | |
| JP 2007515474 | T | 20070614 | JP 2006-546400 | 20041220 |
| US 20070293511 | A1 | 20071220 | US 2007-596646 | 20070529 |
| PRIORITY APPLN. INFO.: | | | US 2003-532044P | P 20031222 |
| | | | WO 2004-IB4293 | W 20041220 |


OTHER SOURCE(S): CASREACT 143:133390; MARPAT 143:133390
 IT 858520-93-1P 858521-24-1P 858523-08-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazolopyrimidines as CRF receptor antagonists)
 RN 858520-93-1 CAPLUS
 CN 2-Pyrrolidinemethanol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858521-24-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858523-08-7 CAPLUS

CN Butanoic acid, 2-[(3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-ylamino)-, methyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 858520-82-8P 858520-83-9P 858520-84-0P

858520-85-1P 858520-86-2P 858520-88-4P

858520-90-8P 858520-91-9P 858520-92-0P

858520-95-3P 858520-97-5P 858520-98-6P
858520-99-7P 858521-01-4P 858521-02-5P
858521-03-6P 858521-04-7P 858521-05-8P
858521-06-9P 858521-07-0P 858521-08-1P
858521-09-2P 858521-10-5P 858521-11-6P
858521-12-7P 858521-13-8P 858521-14-9P
858521-15-0P 858521-16-1P 858521-17-2P
858521-18-3P 858521-19-4P 858521-20-7P
858521-21-8P 858521-22-9P 858521-23-0P
858521-25-2P 858521-26-3P 858521-27-4P
858521-28-5P 858521-29-6P 858521-30-9P
858521-31-0P 858521-32-1P 858521-33-2P
858521-34-3P 858521-35-4P 858521-36-5P
858521-37-6P 858521-38-7P 858521-39-8P
858521-40-1P 858521-41-2P 858521-42-3P
858521-43-4P 858521-44-5P 858521-45-6P
858521-46-7P 858521-47-8P 858521-48-9P
858521-49-0P 858521-50-3P 858521-51-4P
858521-52-5P 858521-53-6P 858521-54-7P
858521-55-8P 858521-56-9P 858521-57-0P
858521-58-1P 858521-59-2P 858521-60-5P
858521-61-6P 858521-62-7P 858521-63-8P
858521-64-9P 858521-65-0P 858521-66-1P
858521-67-2P 858521-68-3P 858521-69-4P
858521-70-7P 858521-71-8P 858521-72-9P
858521-73-0P 858521-74-1P 858521-75-2P
858521-76-3P 858521-77-4P 858521-78-5P
858521-79-6P 858521-80-9P 858521-81-0P
858521-82-1P 858521-83-2P 858521-84-3P
858521-85-4P 858521-86-5P 858521-87-6P
858521-88-7P 858521-89-8P 858521-90-1P
858521-91-2P 858521-92-3P 858521-93-4P
858521-94-5P 858521-95-6P 858521-96-7P
858521-97-8P 858521-98-9P 858521-99-0P
858522-00-6P 858522-01-7P 858522-02-8P
858522-03-9P 858522-04-0P 858522-05-1P
858522-06-2P 858522-07-3P 858522-08-4P
858522-09-5P 858522-10-8P 858522-11-9P
858522-12-0P 858522-13-1P 858522-14-2P
858522-15-3P 858522-17-5P 858522-18-6P
858522-19-7P 858522-20-0P 858522-21-1P
858522-22-2P 858522-23-3P 858522-24-4P
858522-25-5P 858522-26-6P 858522-27-7P
858522-28-8P 858522-29-9P 858522-30-2P
858522-32-4P 858522-33-5P 858522-34-6P
858522-35-7P 858522-36-8P 858522-37-9P
858522-38-0P 858522-39-1P 858522-40-4P
858522-41-5P 858522-42-6P 858522-43-7P
858522-44-8P 858522-45-9P 858522-46-0P
858522-47-1P 858522-48-2P 858522-49-3P
858522-50-6P 858522-51-7P 858522-52-8P
858522-53-9P 858522-54-0P 858522-55-1P
858522-56-2P 858522-57-3P 858522-58-4P
858522-59-5P 858522-60-8P 858522-61-9P
858522-62-0P 858522-63-1P 858522-64-2P
858522-65-3P 858522-66-4P 858522-67-5P
858522-68-6P 858522-69-7P 858522-70-0P
858522-71-1P 858522-72-2P 858522-73-3P
858522-74-4P 858522-75-5P 858522-76-6P


858522-77-7P 858522-78-8P 858522-80-2P
858522-82-4P 858522-83-5P 858522-84-6P
858522-85-7P 858522-86-8P 858522-87-9P
858522-88-0P 858522-89-1P 858522-90-4P
858522-91-5P 858522-92-6P 858522-93-7P
858523-09-8P 858523-14-5P 858523-15-6P
858523-19-0P 858523-20-3P 858523-21-4P
858523-22-5P 858523-23-6P 858523-24-7P
858523-25-8P 858523-26-9P 858523-27-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as CRF receptor antagonists)


RN 858520-82-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 858520-83-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(4-morpholinyl)- (CA INDEX NAME)




RN 858520-84-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858520-85-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858520-86-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,2,5-trimethyl- (CA INDEX NAME)



RN 858520-88-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858520-90-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 858520-91-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,N,2,5-tetramethyl- (CA INDEX NAME)




RN 858520-92-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858520-95-3 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopropyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858520-97-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858520-98-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine, 7-(1-azetidinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858520-99-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-01-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-methylpropyl)- (CA INDEX NAME)




RN 858521-02-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1,1-dimethylethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-03-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 858521-04-7 CAPLUS
 CN Propanenitrile, 3-[(3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)methylamino]- (CA INDEX NAME)




RN 858521-05-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(1H-imidazol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-06-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(2-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)



RN 858521-07-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(1H-benzimidazol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-08-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-(2-ethyl-1H-imidazol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-09-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[2-(1-methylethyl)-1H-imidazol-1-yl]- (CA INDEX NAME)




RN 858521-10-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,4-dimethyl-1H-imidazol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-11-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(phenylmethyl)-N-propyl- (CA INDEX NAME)




RN 858521-12-7 CAPLUS

CN Pyrazole-3-carboxylic acid, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-5-methyl-, methyl ester (CA INDEX NAME)




RN 858521-13-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(4-methyl-1H-imidazol-1-yl)- (CA INDEX NAME)




RN 858521-14-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1H-1,2,4-triazol-1-yl)- (CA INDEX NAME)




RN 858521-15-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,3-dihydro-1H-indol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-16-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2-ethyl-4-methyl-1H-imidazol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-17-2 CAPLUS


CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-3-methyl-
(CA INDEX NAME)




RN 858521-18-3 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 858521-19-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine, 7-(2-ethyl-1-piperidinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-20-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine, 7-(3,6-dihydro-1(2H)-pyridinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-21-8 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(2-methyl-1-piperidinyl)- (CA INDEX NAME)



RN 858521-22-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 858521-23-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 858521-25-2 CAPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)




RN 858521-26-3 CAPLUS

CN 1,2-Ethanediamine, N-ethyl-N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl- (9CI) (CA INDEX NAME)




RN 858521-27-4 CAPLUS

CN 1,2-Ethanediamine, N,N,N'-triethyl-N'-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 858521-28-5 CAPLUS

CN 2-Piperidineethanol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-29-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(2-propyl-1-piperidinyl)- (CA INDEX NAME)




RN 858521-30-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[2-(methoxymethyl)-1-piperidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-31-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[2-(2-methoxyethyl)-1-piperidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-32-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(2,6-dimethyl-1-piperidinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-33-2 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 858521-34-3 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, ethyl ester (CA INDEX NAME)



RN 858521-35-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 858521-36-5 CAPLUS
 CN 3-Piperidinecarboxamide, N,N-diethyl-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-37-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(3,3-dimethyl-1-piperidinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-38-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-(5-ethyl-2-methyl-1-piperidinyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-39-8 CAPLUS

CN 4-Piperidinol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-40-1 CAPLUS

CN 1,2-Ethanedianime, N1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N1,N2,N2-trimethyl-1-phenyl- (CA INDEX NAME)




RN 858521-41-2 CAPLUS

CN 1,2-Ethanedianime, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-tris(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 858521-42-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 858521-43-4 CAPLUS

CN 4-Piperidineethanol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-44-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-(4-fluorophenyl)ethyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-45-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1-piperidinyl)- (CA INDEX NAME)




RN 858521-46-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(3-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 858521-47-8 CAPLUS

CN Quinoline, 1,2,3,4-tetrahydro-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-48-9 CAPLUS

CN Ethanol, 2-[ethyl]3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-ylaminol- (CA INDEX NAME)




RN 858521-49-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-[(2R,4S)-4-fluoro-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 858521-50-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-[3-(trifluoromethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 858521-51-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2,6-dichlorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-52-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-chloro-6-methylphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858521-53-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2,6-difluorophenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858521-54-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-

N,2,5-trimethyl-N-[1-phenyl-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 858521-55-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 858521-56-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[3-(methoxymethyl)-1-piperidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-57-0 CAPLUS


CN Benzenesulfonamide, 4-[[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]- (CA INDEX NAME)



RN 858521-58-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 858521-59-2 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-furanyl methyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-60-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-thienylmethyl)- (CA INDEX NAME)




RN 858521-61-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-62-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 858521-63-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(4-(trifluoromethoxy)phenyl)methyl]- (CA INDEX NAME)




RN 858521-64-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 858521-65-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(4-(methylsulfonyl)phenyl)methyl]- (CA INDEX NAME)




RN 858521-66-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-67-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-68-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 858521-69-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-70-7 CAPLUS


CN 1-Butanol, 2-[[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 858521-71-8 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)propyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858521-72-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[3-(trifluoromethyl)phenylmethyl]- (CA INDEX NAME)




RN 858521-73-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[3-(difluoromethoxy)phenylmethyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-74-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3,4-difluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-75-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-chlorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-76-3 CAPLUS

CN Benzonitrile, 3-chloro-4-[(3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-5-methyl- (CA INDEX NAME)




RN 858521-77-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-chloro-4,6-dimethylphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-78-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-chloro-4,6-dimethoxyphenyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-79-6 CAPLUS


CN Benzonitrile, 3,5-dichloro-2-[(3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]amino)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (CA INDEX NAME)




RN 858521-80-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-fluoro-6-(trifluoromethyl)phenyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-81-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 858521-82-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[{(3-chloro-4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858521-83-2 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[{(4-chlorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-84-3 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[{4-(difluoromethoxy)phenylmethyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-85-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3,4-dichlorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-86-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)




RN 858521-87-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(5-methyl-2-furanyl)methyl]- (CA INDEX NAME)




RN 858521-88-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(5-(2-pyridinyl)-2-thienenyl)methyl]- (CA INDEX NAME)




RN 858521-89-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(2-thiazolylmethyl)- (CA INDEX NAME)




RN 858521-90-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(3-methyl-2-thienyl)methyl]- (CA INDEX NAME)




RN 858521-91-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]- (CA INDEX NAME)




RN 858521-92-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(2,5-dimethyl-3-furanyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858521-93-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)



RN 858521-94-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3,5-dimethyl-4-isoxazolyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858521-95-6 CAPLUS


CN 1-Butanol, 2-[(3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 858521-96-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 858521-97-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (CA INDEX NAME)




RN 858521-98-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)



RN 858521-99-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (CA INDEX NAME)




RN 858522-00-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (CA INDEX NAME)



RN 858522-01-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 858522-02-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-7-(1H-pyrrolo[2,3-b]pyridin-1-yl)- (CA INDEX NAME)




RN 858522-03-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine, 7-(2-ethyl-1H-pyrrol-1-yl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-04-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[4-(1H-imidazol-1-yl)-2-methoxyphenyl]-2,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)



RN 858522-05-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 858522-06-2 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)propyl]-3-[2-methoxy-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858522-07-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-08-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-1,2,3-triazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-09-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(4-methyl-1H-pyrazol-1-yl)phenyl]-7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.






RN 858522-12-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 858522-13-1 CAPLUS
 CN 1H-Pyrrole-2-carbonitrile, 1-[3-methoxy-4-[7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 858522-14-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrrrol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858522-15-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrrrol-1-yl)phenyl]-2,5-dimethyl-N-(3,3,3-trifluoropropyl)- (CA INDEX NAME)




RN 858522-17-5 CAPLUS

CN Propanedioic acid, ethyl [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858522-16-4
CMF C28 H32 N6 O5

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 858522-18-6 CAPLUS
CN 2-Thiophenecarboxylic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-19-7 CAPLUS

CN Propanoic acid, 3-(methylthio)-, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-20-0 CAPLUS

CN Pentanedioic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-21-1 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxylic acid, 4-methyl-, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-22-2 CAPLUS

CN Cyclobutane carboxylic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-23-3 CAPLUS

CN Cyclopropane carboxylic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-24-4 CAPLUS

CN 4-Pyridinecarboxylic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-25-5 CAPLUS

CN Acetic acid, methoxy-, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-26-6 CAPLUS

CN Carbonic acid, ethyl [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 858522-27-7 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, propanoate (ester), (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 858522-28-8 CAPLUS

CN Propanedioic acid, [(2S)-1-{3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl}-2-pyrrolidinyl]methyl methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-29-9 CAPLUS

CN Propanoic acid, 2-methyl-, [(2S)-1-{3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl}-2-pyrrolidinyl]methyl methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-30-2 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-, acetate (ester), (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858522-32-4 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(ethoxymethyl)-1-pyrrolidinyl]-3-(2-methoxy-4-(1H-pyrazol-1-yl)phenyl)-2,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858522-31-3

CMF C25 H30 N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 858522-33-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-[(2,2-dimethoxyethoxy)methyl]-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-34-6 CAPLUS

CN Acetonitrile, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 858522-35-7 CAPLUS


CN Acetic acid, [(2S)-1-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl]methoxy-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 858522-36-8 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-fluoroethyl)-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-37-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-fluoroethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-38-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-fluoroethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,2,5-trimethyl- (CA INDEX NAME)



RN 858522-39-1 CAPLUS
CN 1,2-Ethanediame, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-(2-methylpropyl)-(9CI) (CA INDEX NAME)




RN 858522-40-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 858522-41-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-42-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-N-[(3-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-43-7 CAPLUS
CN Benzonitrile, 3-[(2-methoxyethyl)[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl] - (CA INDEX NAME)



RN 858522-44-8 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1,3-benzodioxol-5-ylmethyl)-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-45-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(3-fluorophenyl)methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-46-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1*H*-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-47-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1*H*-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(2-methyl-4-thiazolyl)methyl]- (CA INDEX NAME)




RN 858522-48-2 CAPLUS

CN Benzonitrile, 4-[(2-methoxyethyl)[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl] - (CA INDEX NAME)




RN 858522-49-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[4-(difluoromethoxy)phenyl]methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858522-50-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[{3-(difluoromethoxy)phenyl}methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-
 (CA INDEX NAME)




RN 858522-51-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[{3-(trifluoromethoxy)phenyl}methyl]-
 (CA INDEX NAME)




RN 858522-52-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(4-(trifluoromethoxy)phenyl)methyl]-
(CA INDEX NAME)




RN 858522-53-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(3-pyridinylmethyl)-
(CA INDEX NAME)




RN 858522-54-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[[2-(trifluoromethoxy)phenyl]methyl]-
(CA INDEX NAME)




RN 858522-55-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[[2-(difluoromethoxy)phenyl]methyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-
(CA INDEX NAME)




RN 858522-56-2 CAPLUS

CN 1,2-Ethanediamine, N-[(4-fluorophenyl)methyl]-N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl- (9CI) (CA INDEX NAME)




RN 858522-57-3 CAPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-[(4-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 858522-58-4 CAPLUS

CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-[(3-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 858522-59-5 CAPLUS


CN 1,2-Ethanediamine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N',N'-dimethyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 858522-60-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-N-ethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



RN 858522-61-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-62-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(4-(trifluoromethoxy)phenyl)methyl]- (CA INDEX NAME)




RN 858522-63-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(3-(trifluoromethoxy)phenyl)methyl]-
(CA INDEX NAME)




RN 858522-64-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-ethoxyethyl)-N-[(3-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-
(CA INDEX NAME)




RN 858522-65-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 858522-66-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 858522-67-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 858522-68-6 CAPLUS

CN Propanenitrile, 3-[ethyl[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 858522-69-7 CAPLUS

CN Propanenitrile, 3-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino- (CA INDEX NAME)




RN 858522-70-0 CAPLUS

CN Propanenitrile, 3-[cyclopropyl[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 858522-71-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[3-(1H-imidazol-1-yl)propyl]-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858522-72-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 858522-73-3 CAPLUS

CN Propanenitrile, 3-[2-(3,4-dimethoxyphenyl)ethyl][3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino- (CA INDEX NAME)




RN 858522-74-4 CAPLUS

CN Propanenitrile, 3-[{3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl}(2-thienylmethyl)amino]- (CA INDEX NAME)




RN 858522-75-5 CAPLUS

CN Propanenitrile, 3-[{3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl}[2-(2-pyridinyl)ethyl]amino]- (CA INDEX NAME)




RN 858522-76-6 CAPLUS

CN Propanenitrile, 3-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl][3-(4-morpholinyl)propyl]amino-
(CA INDEX NAME)




RN 858522-77-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-N,2,5-trimethyl-
N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 858522-78-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 858522-80-2 CAPLUS

CN Butanoic acid, 4-[(3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858522-79-9

CMF C29 H30 N6 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 858522-82-4 CAPLUS
CN Butanoic acid, 4-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino-, ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858522-81-3
CMF C31 H34 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 858522-83-5 CAPLUS
CN Heptanoic acid, 7-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino-, ethyl ester (CA INDEX NAME)




RN 858522-84-6 CAPLUS

CN Octanoic acid, 8-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino-, ethyl ester
(CA INDEX NAME)




RN 858522-85-7 CAPLUS

CN Pentanoic acid, 5-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino-, ethyl ester
(CA INDEX NAME)




RN 858522-86-8 CAPLUS

CN Hexanoic acid, 6-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino-, ethyl ester
(CA INDEX NAME)




RN 858522-87-9 CAPLUS

CN Heptanoic acid, 7-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino- (CA INDEX NAME)




RN 858522-88-0 CAPLUS

CN Pentanoic acid, 5-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino- (CA INDEX NAME)




RN 858522-89-1 CAPLUS

CN Hexanoic acid, 6-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino- (CA INDEX NAME)




RN 858522-90-4 CAPLUS

CN Octanoic acid, 8-[(3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)(phenylmethyl)amino]- (CA INDEX NAME)




RN 858522-91-5 CAPLUS

CN β -Alanine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(phenylmethyl)-, ethyl ester (CA INDEX NAME)




RN 858522-92-6 CAPLUS

CN β-Alanine, N-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 858522-93-7 CAPLUS


CN Nonanoic acid, 9-[3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl](phenylmethyl)amino]- (CA INDEX NAME)



RN 858523-09-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 858523-14-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl-N-(3,3,3-trifluoropropyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 858523-13-4
CMF C24 H27 F3 N6 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 858523-15-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(3-fluoropropyl)-N-(2-methoxyethyl)-3-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)



CM 1

CRN 858523-18-9
CMF C24 H28 N4 O3



CM 2


CRN 76-05-1
CMF C₂ H F₃ O₂



RN 858523-20-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858523-21-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(3-pyridinyl)phenyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 858523-22-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidine, 3-[2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl]-7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 858523-23-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-[2-methoxy-4-(3-thienyl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858523-24-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-[4-(2-furanyl)-2-methoxyphenyl]-N-(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



RN 858523-25-8 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-[2-methoxy-4-(2-thienyl)phenyl]-2,5-dimethyl- (CA INDEX NAME)




RN 858523-26-9 CAPLUS
CN 1H-Pyrrole-1-carboxylic acid, 2-[4-(7-[ethyl(2-methoxyethyl)amino]-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)-3-methoxyphenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 858523-27-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine, 7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-[2-methoxy-4-(2-oxazolyl)phenyl]-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 858523-70-3 858523-71-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolopyrimidines as CRF receptor antagonists)

RN 858523-70-3 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-bromo-2-methoxyphenyl)-N-ethyl-N-(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 858523-71-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine, 3-(4-bromo-2-methoxyphenyl)-7-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



IT 858523-42-9P 858523-43-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolo[1,5-a]pyrimidines as CRF receptor antagonists)
 RN 858523-42-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-bromo-2-methoxyphenyl)-2,5-dimethyl-
 N-(1-methylethyl)- (CA INDEX NAME)



RN 858523-43-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-iodo-2-methoxyphenyl)-2,5-dimethyl-
 N-(1-methylethyl)- (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, NH2, (un)substituted alkyl, etc.; R2 = NR5R6 or OR7; R3 = H, alkyl or absent if double bond is present; Y = CO, =(CR4)-;


R4 = H, thioalkyl, (un)substituted alkyl, etc.; Ar = (un)substituted Ph or pyridyl; Het = (un)substituted heteroaryl; R5 = H, (un)substituted alkyl, heterocycle, etc.; R6 = (un)substituted alkyl, heterocyclealkyl, aryl, etc.; R7 = (un)substituted alkyl, arylalkyl, heteroarylalkyl, etc.) and their pharmaceutically acceptable salts, are prepared and disclosed as CRF receptor antagonists. Thus, e.g., II was prepared by cyclization of III (preparation given) with Et acetoacetate followed by chlorination and subsequent substitution with isopropylamine. The CRF receptor binding activity of I was evaluated using radioligand binding assay (no data). I as CRF receptor antagonists should prove useful in the treatment of stroke, depression and anxiety. Pharmaceutical compns. comprising I are disclosed.

REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 9 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:461608 CAPLUS
 DOCUMENT NUMBER: 143:185966
 TITLE: The pharmacology of DMP696 and DMP904, non-peptidergic
 CRF1 receptor antagonists
 AUTHOR(S): Li, Yu-Wen; Fitzgerald, Lawrence; Wong, Harvey; Lelas,
 Snjezana; Zhang, Ge; Lindner, Mark D.; Wallace, Tanya;
 McElroy, John; Lodge, Nicholas J.; Gilligan, Paul;
 Zaczek, Robert
 CORPORATE SOURCE: Neuroscience Biology, Medicinal Chemistry, Metabolism
 and Pharmacokinetics, Bristol-Myers Squibb
 Pharmaceutical Research Institute, Wallingford, CT,
 USA
 SOURCE: CNS Drug Reviews (2005), 11(1), 21-52
 CODEN: CDREFB; ISSN: 1080-563X
 PUBLISHER: Neva Press
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 IT 202579-74-6, DMP904
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pharmacol. properties suggested that non-peptidergic CRF1 receptor
 antagonists DMP696 and DMP904 may be effective anxiolytics with low
 behavioral side effect liabilities in rat model of anxiety)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-
 methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB A review. CRF1 antagonists DMP696 and DMP904 were designed as drug development candidates for the treatment of anxiety and depression. Both compds. display nanomolar affinity for human CRF1 receptors, and exhibit > 1000-fold selectivity for CRF1 over CRF2 receptors and over a broad panel of other proteins. DMP696 and DMP904 block CRF-stimulated adenylyl cyclase activity in cortical homogenates and cell-lines expressing CRF1 receptors. Both compds. inhibit CRF-stimulated ACTH release from rat pituitary corticotropes. Binding and functional studies indicate that DMP696 and DMP904 behave as noncompetitive full antagonists. DMP696 and DMP904 exhibit anxiolytic-like efficacy in several rat anxiety models. In the defensive withdrawal test, both compds. reduce exit latency with lowest EDs of 3 and 1 mg/kg, resp. The anxiolytic-like effect is maintained over 14 days of repeated dosing. In the context of a novel environment used in this test, DMP696 and DMP904 reverse mild stress-induced increases in plasma CORT secretion but at doses 3-4-fold greater than those required for anxiolytic-like efficacy. DMP696 and DMP904 are ineffective in three depression models including the learned helplessness paradigm at doses up to 30 mg/kg. At lowest anxiolytic-like doses, DMP696 and DMP904 occupy >50% CRF1 receptors in the brain. The in vivo IC50 values (plasma concns. required for occupying 50% CRF1

receptors) estimated based upon free, but not total, plasma concns. are an excellent correlation with the in vitro IC₅₀ values. Neither compound produces sedation, ataxia, chlordiazepoxide-like subjective effects or adverse effects on cognition at doses 10-fold higher than anxiolytic-like doses. Neither compound produces physiol. significant changes in cardiovascular, respiratory, gastrointestinal or renal functions at anxiolytic-like doses. DMP696 and DMP904 have favorable pharmacokinetic profiles with good oral bioavailabilities. The overall pharmacol. properties suggest that both compds. may be effective anxiolytics with low behavioral side effect liabilities.

REFERENCE COUNT: 108 THERE ARE 108 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

ACCESSION NUMBER: 2005:268104 CAPLUS

DOCUMENT NUMBER: 143:19806

TITLE: Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats

AUTHOR(S): Wong, Harvey; Lehman-McKeeman, Lois D.; Grubb, Mary F.; Grossman, Scott J.; Bhaskaran, Vasanthi M.; Solon, Eric G.; Shen, Helen S. L.; Gerson, Ronald J.; Car, Bruce D.; Zhao, Bitao; Gemzik, Brian

CORPORATE SOURCE: Departments of Metabolism and Pharmacokinetics, Discovery Toxicology and Biotransformation, Pharmaceutical Candidate Optimization, 5 Research Parkway, Wallingford, Connecticut, Bristol-Myers Squibb Company, Princeton, NJ, 08543, USA


SOURCE: Toxicological Sciences (2005), 84(2), 232-242
CODEN: TOSCF2; ISSN: 1096-6080PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal

LANGUAGE: English

IT 202579-74-6, DMP 904
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(increased hepatobiliary clearance of unconjugated thyroxine dets. DMP 904-induced alterations in thyroid hormone homeostasis in rats)

RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB 4-(3-Pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine (DMP 904) is a potent and selective antagonist of corticotropin releasing factor receptor-1 (CRF1 receptor) with an efficacious anxiolytic profile in preclin. animal models. In subchronic toxicity studies in Sprague-Dawley rats, DMP 904 produced thyroid follicular cell hypertrophy and hyperplasia, and a low incidence of follicular cell adenoma. The current investigations were designed to determine the mode of action by which DMP 904 disrupts thyroid homeostasis in male rats. Five-day treatment with DMP 904 (300 mg/kg/day) dramatically lowered serum thyroxine (T4) to levels below detectable limits (<1 µg/dL) by 72 h, with concurrent decreases in triiodothyronine (T3, about a 70% decrease) and increases in TSH (TSH; about a three-fold increase). DMP 904 increased [125I]T4 total body clearance (Cl_{tb}) (38.21±10.45 mL/h) compared to control (5.61±0.59 mL/h) and phenobarbital-treated rats (7.92±1.62 mL/h). This increase in Cl_{tb} was associated with a significant increase in biliary clearance (Cl_{bile}) of unconjugated [125I]T4 (nearly 80-times control rates) and increased liver:blood ratios of T4, suggestive of enhanced hepatic uptake of T4. A single dose of DMP 904 (200 mg/kg) increased mRNA levels of hepatic

cytochrome P450s (CYP 3A1 and CYP 2B1) and UDP-glucuronosyltransferases (UGT 1A1 and UGT 1A2). DMP 904 also induced mRNAs of the canalicular transporter, multi-drug resistance protein-2 (Mrp2), and sinusoidal transporters, organic anion transporting proteins (Oatpl and Oatp2) within 24 h. Western blot anal. confirmed DMP 904 related increases in Oatp2 protein expression. Collectively, these data suggest that DMP 904 is an agonist of the constitutive androstane receptor (CAR) and pregnane X receptor (PXR) and that the decreased serum levels of T4 and T3 resulted from increased hepatobiliary clearance. However, DMP 904 is distinguished from other compds. associated with similar effects on thyroid hormone homeostasis because its effects were primarily related to increased biliary excretion of unconjugated T4.

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 11 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005;222553 CAPLUS
 DOCUMENT NUMBER: 142:385821
 TITLE: Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests
 AUTHOR(S): Hogan, John B.; Hodges, Donald B., Jr; Lelas, Snjezana; Gilligan, Paul J.; McElroy, John F.; Lindner, Mark D.
 CORPORATE SOURCE: Neuroscience Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492, USA
 SOURCE: Psychopharmacology (Berlin, Germany) (2005), 178(4), 410-419
 CODEN: PSCHDL; ISSN: 0033-3158
 PUBLISHER: Springer GmbH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP-904
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CRF1 receptor antagonists and benzodiazepines on cognitive functions)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB Benzodiazepines continue to be widely used for the treatment of anxiety, but it is well known that benzodiazepines have undesirable side effects, including sedation, ataxia, cognitive deficits, and the risk of addiction and abuse. CRF1 receptor antagonists are being developed as potential novel anxiolytics, but while CRF1 receptor antagonists seem to have a better side-effect profile than benzodiazepines with respect to sedation and ataxia, the effects of CRF1 receptor antagonists on cognitive function were not well characterized. It is somewhat surprising that the potential cognitive effects of CRF1 receptor antagonists were not more fully characterized since there is some evidence to suggest that these compds. may impair cognitive function. The Morris water maze and the delayed non-matching to position test are sensitive tests of a range of cognitive functions, including spatial learning, attention, and short-term memory, so the objective of the present expts. was to assess the effects of benzodiazepines and CRF1 receptor antagonists in these tests. The benzodiazepines clordiazepoxide and alprazolam disrupted performance in the Morris water maze and delayed non-matching to position at doses close to their therapeutic, anxiolytic doses. In contrast, the CRF1 receptor antagonists DMP-904 and DMP-696 produced little or no impairment in the Morris water maze or delayed non-matching to position test even at doses 10-fold higher than were necessary to produce anxiolytic effects. The results of the present expts. suggest that, with respect to their effects

on cognitive functions, CRF1 receptor antagonists seem to have a wider therapeutic index than benzodiazepines.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 12 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:750991 CAPLUS
 DOCUMENT NUMBER: 141:271427
 TITLE: Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice
 AUTHOR(S): Nielsen, Darcia M.; Carey, Galen J.; Gold, Lisa H.
 CORPORATE SOURCE: Pfizer, Kalamazoo, MI, 49007, USA
 SOURCE: European Journal of Pharmacology (2004), 499(1-2), 135-146
 CODEN: EJPRAZ; ISSN: 0014-2999
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP 904
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB The development of selective corticotropin-releasing factor type-1 (CRF1) receptor antagonists represents a potential novel treatment for depression. These studies evaluated CRF1 receptor antagonists for antidepressant-like activity in mice. Subchronic dosing of both R 121919 (3-[6-(dimethylamino)-4-methyl-pyrid-3-yl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidin-7-amine) and DMP 696 (4-(1,3-dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)-pyrazolo[1,5-a]-1,3,5-triazine) significantly decreased immobility time in the tail suspension test (at 30 and at 3 and 10 mg/kg, i.p., resp.). These antidepressant-like effects were observed at doses that did not impair general locomotor activity. Neither antalarmin (N-butyl-N-ethyl-[2,5,6-trimethyl-1-(2,4,6-trimethylphenyl)]-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine) nor DMP 904 (4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine) had an effect indicative of antidepressant-like activity. These results suggest that the tail suspension assay may have utility to identify CRF1 receptor antagonists with antidepressant-like activity. Moreover, the results lend support to the theory that some nonpeptidic CRF1 receptor antagonists may possess antidepressant-like activity and therefore represent a promising novel pharmacotherapeutic strategy in the treatment of depression.

REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 13 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:523288 CAPLUS
 DOCUMENT NUMBER: 141:225452
 TITLE: Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists
 AUTHOR(S): Huang, Charles Q.; Wilcoxen, Keith M.; Grigoriadis, Dimitri E.; McCarthy, James R.; Chen, Chen
 CORPORATE SOURCE: Department of Medicinal Chemistry and Department of Pharmacology, Neurocrine Biosciences, Inc., San Diego, CA, 92129, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(15), 3943-3947
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:225452
 IT 195054-99-0, NBI 30545 202579-74-6, DMP 904
 RL: PRP (Properties)
 (calculated lipophilicity of corticotropin-releasing factor receptor antagonists)
 RN 195054-99-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




GI




AB A series of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines I [R1 = Cl, O2N, Me, F3C, H2N, HO, etc.; R2 = H, Me, Cl, O2N, H2N, MeO, NO, etc.; R3, R4 = n-Pr, n-Bu, MeOCH₂CH₂, cyclopropylmethyl, PhCH₂] was designed and synthesized as antagonists for the corticotropin-releasing factor-1 (CRF1) receptor. Several compds. such as I [R1 = Me2N; R2 = Me; R3 = R4 = n-Pr; (II)] (Ki = 10 nM) exhibited good binding affinities at the CRF1 receptor. In addition, II had adequate solubility in water.


LS ANSWER 14 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:498562 CAPLUS
 DOCUMENT NUMBER: 141:207163
 TITLE: Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility
 AUTHOR(S): Chen, Chen; Wilcoxen, Keith M.; Huang, Charles Q.; McCarthy, James R.; Chen, Takung; Grigoriadis, Dimitri E.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Neurocrine Biosciences, Inc., San Diego, CA, 92121, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3669-3673
 CODEN: BMCLB8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:207163
 IT 195055-89-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility)
 RN 195055-89-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-methoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




IT 195054-99-0P 195055-79-9P 195055-83-5P
 195055-85-7P 195055-86-8P 195055-88-0P
 744222-20-6P 744222-21-7P 744222-22-8P
 744222-23-9P 744222-24-0P 744222-32-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility)
 RN 195054-99-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 195055-79-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 195055-83-5 CAPLUS
 CN Ethanol, 2-[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino- (CA INDEX NAME)




RN 195055-85-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 195055-86-8 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(2,4-dimethoxyphenyl)-N-ethyl-
2,5-dimethyl- (CA INDEX NAME)




RN 195055-88-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxyphenyl)-2,5-dimethyl-N,N-
dipropyl- (CA INDEX NAME)




RN 744222-20-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-methoxyphenyl)-2,5-dimethyl-N,N-
dipropyl- (CA INDEX NAME)




RN 744222-21-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(4-
methoxyphenyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 744222-22-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 744222-23-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 744222-24-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



RN 744222-32-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-[4-[2-(dimethylamino)ethoxy]phenyl]-
 2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)



GI



I

AB In an effort to identify potent CRF1 antagonists with proper physicochem. properties, a series of 3-phenylpyrazolo[1,5-a]pyrimidines bearing polar groups, such as amino, hydroxyl, methoxy, sulfoxide, were designed and synthesized. Several positions of the core structure were identified, where a polar group was tolerated with slight reduction in receptor binding. NBI 30545 (I) was found to have good binding affinity and potent antagonistic activity at the human CRF1 receptor. Moreover, this compound had proper lipophilicity ($\log D = 2.78$) and good solubility in water (>10 mg/mL), and exhibited good plasma and brain exposure when given orally.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:292574 CAPLUS
DOCUMENT NUMBER: 140:368553

TITLE: Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]pyrimidine] administered acutely or chronically at doses occupying central CRF1 receptors in rats

AUTHOR(S): Lelas, Snejzana; Wong, Harvey; Li, Yu-Wen; Heman, Karen L.; Ward, Kathryn A.; Zeller, Kim L.; Sieracki, Kristine K.; Polino, Joseph L.; Godonis, Helen E.; Ren, Shelly X.; Yan, Xiao-Kin; Arneric, Stephen P.; Robertson, David W.; Hartig, Paul R.; Grossman, Scott; Trainor, George L.; Taub, Rebecca A.; Zaczek, Robert; Gilligan, Paul J.; McElroy, John F.

CORPORATE SOURCE: Neuroscience Biology, Bristol-Myers Squibb Company, Wallingford, CT, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2004), 309(1), 293-302

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics


DOCUMENT TYPE: Journal
LANGUAGE: English

IT 202579-74-6, DMP 904

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); BIOL (Biological study)
(anxiolytic-like effects of chronic or acute corticotropin-releasing factor1 (CRF1) antagonist DMP904)

RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB Corticotropin-releasing factor1 (CRF1) antagonists may be effective in the treatment of anxiety disorders with fewer side effects compared with classic benzodiazepines. The behavioral effects of DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]pyrimidine] and its effects on the hypothalamic-pituitary-adrenal (HPA) axis were related to its levels in plasma and estimated occupancy of central CRF1 receptors. DMP904 (10-30 mg/kg, p.o.) and alprazolam (10 mg/kg, p.o.) increased time spent in open arms of an elevated-plus maze. In addition, acutely or chronically (14 days) administered DMP904 (1.0-30 mg/kg, p.o.) and acute alprazolam (1.0-3.0 mg/kg, p.o.) significantly reduced exit latency in the defensive withdrawal model of anxiety in rats, suggesting that tolerance may not develop to the anxiolytic-like effects of DMP904 in this model of anxiety. Acutely, DMP904 reversed the stress-induced increase in plasma corticosterone levels in defensive

withdrawal at doses of 3.0 mg/kg and higher. These doses also resulted in levels of DMP904 in plasma similar to (for anxiolytic-like effects) or 4-fold higher (for effects on the HPA axis) than the in vitro IC₅₀ value for binding affinity at CRF1 receptors and greater than 50% occupancy of CRF1 receptors. Unlike alprazolam, DMP904 did not produce sedation, ataxia, or chlordiazepoxide-like subjective effects (as measured by locomotor activity, rotarod performance, and chlordiazepoxide discrimination assays, resp.) at doses at least 3-fold higher than anxiolytic-like doses. In conclusion, anxiolytic-like effects and effects on the stress-activated HPA axis of DMP904 in the defensive withdrawal model of anxiety required 50% or greater occupancy of central CRF1 receptors. This level of CRF1 receptor occupancy resulted in fewer motoric side effects compared with classic benzodiazepines.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 16 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:262469 CAPLUS
 DOCUMENT NUMBER: 139:173737
 TITLE: Pharmacological characterization of a novel nonpeptide antagonist radioligand, (\pm)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl)propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([³H]SN003) for corticotropin-releasing factor receptors
 AUTHOR(S): Zhang, Ge; Huang, Ning; Li, Yu-Wen; Qi, Xiaoping; Marshall, Anne P.; Yan, Xiao-Xin; Hill, Geraldine; Rominger, Cynthia; Prakash, Shimoga R.; Bakthavatchalam, Rajagopal; Rominger, David H.; Gilligan, Paul J.; Zaczek, Robert
 CORPORATE SOURCE: CNS Diseases Research, Bristol-Myers Squibb Pharmaceutical Research Institute, Wilmington, DE, USA
 SOURCE: Journal of Pharmacology and Experimental Therapeutics (2003), 305(1), 57-69
 CODEN: JPETAB; ISSN: 0022-3565
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6, DMP 904
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (pharmacol. characterization of a novel nonpeptide antagonist radioligand, (\pm)-N-[2-Me-4-methoxyphenyl]-1-(1-(methoxymethyl)propyl)-6-Me-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([³H]SN003) for corticotropin-releasing factor receptors)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB The in vitro pharmacol. profile of a novel small mol. corticotropin-releasing factor 1 (CRF1) receptor antagonist, (\pm)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl)propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine (SN003), and the characteristics of its radioligand ([³H]SN003) are described. SN003 has high affinity and selectivity for CRF1 receptors expressed in rat cortex, pituitary, and recombinant HEK293EBNA (HEK293e) cells with resp. radiolabeled ovine CRF ([¹²⁵I]oCRF) binding Ki values of 2.5, 7.9, and 6.8 nM. SN003 was shown to be a CRF1 receptor antagonist inasmuch as it inhibited CRF-induced cAMP accumulation in human CRF1HEK293e cells and CRF-stimulated ACTH hormone release from rat pituitary cells without agonist activities. Significant decreases in the Bmax of [¹²⁵I]oCRF binding by SN003 suggest that this antagonist is not simply competitive. To further explore the interaction of SN003 with the CRF1 receptors, [³H]SN003 binding to rat cortex and human CRF1HEK293e cell membranes was characterized and shown to be reversible and saturable,

with KD values of 4.8 and 4.6 nM, and Bmax values of 0.142 and 7.42 pmol/mg protein, resp. The association and dissociation rate consts. of [3H]SN003 ($k_+ 1$ 0.292 nM $^{-1}$ min $^{-1}$ and $k_- 0.992 \times 10^{-2}$ min $^{-1}$) were also assessed using human CRF1HEK293e cell membranes, giving an equilibrium dissociation constant of 3.4 nM. Moreover, [3H]SN003 binding displayed a single affinity state and insensitivity to 5'-guanylylimidodiphosphate, consistent with characteristics of antagonist binding. Incomplete inhibition of [3H]SN003 binding by CRF peptides also suggests that SN003 is not simply competitive with CRF at CRF1 receptors. The distribution of [3H]SN003 binding sites was consistent with the expression pattern of CRF1 receptors in rat brain regions. Small mol. CRF1 antagonist radioligands like [3H]SN003 should enable a better understanding of small mol. interactions with the CRF1 receptor.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:716091 CAPLUS

DOCUMENT NUMBER: 137:232665

TITLE: A process for the preparation of a homochiral corticotropin releasing factor receptor ligand

INVENTOR(S): Gilligan, Paul J.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA

SOURCE: PCT Int. Appl., 44 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2002072101 | A1 | 20020919 | WO 2002-US6834 | 20020306 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2002240578 | A1 | 20020924 | AU 2002-240578 | 20020306 |
| PRIORITY APPLN. INFO.: | | | US 2001-275331P | P 20010313 |
| | | | WO 2002-US6834 | W 20020306 |

OTHER SOURCE(S): CASREACT 137:232665

IT 457911-55-6P, (-)-7-((R)-Butan-2-ylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CRF antagonist; process for preparation of a homochiral corticotropin releasing factor receptor ligand)


RN 457911-55-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-methylpropyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



AB A process for the preparation of corticotropin releasing factor receptor I was disclosed. 2-Methyl-4-methoxybenzyl bromide (prepn given) was converted to the nitrile (DMF/EtOHaq, NaCN) and acetylated (EtOAc, Na⁺, reflux) and reacted with hydrazine to give an intermediate pyrazole. This was reacted with Et acetoacetate (HOAc, reflux) to form 7-hydroxy-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl)pyrazolo[1,5-a]pyrimidine (II). II was treated with POC13 (PhMe, DIEA) and the chloride displaced with (R)-2-butylamine to afford I. I is used in treating anxiety, depression, and other psychiatric, neurol. disorders as well as treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress.


REFERENCE COUNT:

1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 18 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:184863 CAPLUS
 DOCUMENT NUMBER: 136:221516
 TITLE: Hair growth stimulants containing CRF1 receptor antagonists
 INVENTOR(S): Ikeda, Akiko; Okuyama, Shigeru; Shibasaki, Tamotsu;
 Kawana, Seiji; Kaneko, Katsumi
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 2002019975 | A1 | 20020314 | WO 2001-JP7537 | 20010831 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, IJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001084417 | A5 | 20020322 | AU 2001-84417 | 20010831 |
| PRIORITY APPLN. INFO.: | | | JP 2000-269291 | A 20000905 |
| | | | WO 2001-JP7537 | W 20010831 |

OTHER SOURCE(S): MARPAT 136:221516
 IT 195054-99-0 202579-74-6
 RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (hair growth stimulants containing CRF1 receptor antagonists)
 RN 195054-99-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-
 methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-
 methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB Disclosed are hair growth stimulants containing a corticotropin release factor (CRF) 1 receptor antagonist as the active ingredient. A CRF1 receptor antagonist 2-[N-(2-methylthio-4-isopropylphenyl)-N-ethylamino]-4-[4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridine-1-yl]-6-methylpyrimidine showed keratinocyte cell proliferation promoting effect in cultured human epidermal keratinocyte cells.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 19 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:813420 CAPLUS
 DOCUMENT NUMBER: 135:344507
 TITLE: Preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis, Argyrios Georgios
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA
 SOURCE: U.S., 57 pp., Cont.-in-part of U.S. Ser. No. 899,242.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|--|----------|
| US 6313124 | B1 | 20011106 | US 1998-14734 | 19980128 |
| CA 2532925 | A1 | 19980129 | CA 1997-2532925 | 19970723 |
| US 6124289 | A | 20000926 | US 1997-899242 | 19970723 |
| EP 1908764 | A1 | 20080409 | EP 2007-15514 | 19970723 |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT,
SE, AL, LT, LV, RO, SI | A | 19990125 | ZA 1997-6603 | 19970724 |
| ZA 9706603 | A | 20001024 | US 1998-14999 | 19980128 |
| US 6136809 | A | 20000725 | LT 1999-8 | 19990125 |
| LT 4680 | B | 20000725 | CA 1999-2314613 | 19990128 |
| CA 2314613 | A1 | 19990805 | CA 1999-2614603 | 19990128 |
| CA 2614603 | A1 | 19990805 | WO 1999-US1824 | 19990128 |
| WO 9938868 | A1 | 19990805 | W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL,
RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | 19990128 |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE | A | 19990816 | AU 1999-24787 | 19990128 |
| AU 9924787 | A | 20020613 | AU 1999-24787 | 19990128 |
| AU 748818 | B2 | 20020613 | EP 1999-904382 | 19990128 |
| EP 1049699 | A1 | 20001108 | EP 1999-904382 | 19990128 |
| EP 1049699 | B1 | 20040421 | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO | 19990128 |
| BR 9908206 | A | 20001205 | BR 1999-8206 | 19990128 |
| JP 2002501922 | T | 20020122 | JP 2000-529335 | 19990128 |
| NZ 505079 | A | 20030829 | NZ 1999-505079 | 19990128 |
| EP 1344779 | A1 | 20030917 | EP 2003-75887 | 19990128 |
| EP 1344779 | B1 | 20050810 | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO | 19990128 |
| AT 264860 | T | 20040515 | AT 1999-904382 | 19990128 |
| PT 1049699 | T | 20040831 | PT 1999-904382 | 19990128 |
| CN 1542010 | A | 20041103 | CN 2003-10122546 | 19990128 |
| ES 2218991 | T3 | 20041116 | ES 1999-904382 | 19990128 |
| SG 111076 | A1 | 20050530 | SG 2002-4556 | 19990128 |
| AT 301657 | T | 20050815 | AT 2003-75887 | 19990128 |
| PT 1344779 | T | 20051031 | PT 2003-75887 | 19990128 |
| ES 2247478 | T3 | 20060301 | ES 2003-75887 | 19990128 |
| TW 520372 | B | 20030211 | TW 1999-88102636 | 19990223 |
| MX 2000PA06495 | A | 20011011 | MX 2000-PA6495 | 20000629 |
| US 20030008885 | A1 | 20030109 | US 2001-930782 | 20010816 |
| US 7094782 | B1 | 20060822 | US 2003-703235 | 20031107 |
| HK 1060348 | A1 | 20051021 | HK 2004-101985 | 20040317 |

JP 2005097257
US 20060252756
PRIORITY APPLN. INFO.:

A 20050414
A1 20061109

JP 2004-216483
US 2006-477680
US 1996-23290P
US 1997-899242
US 1996-686047
CA 1997-2259583
EP 1997-936222
JP 1998-507233
US 1998-14734
US 1998-15001
US 1998-15002
CA 1999-2314613
EP 1999-904382
WO 1999-US1824
US 2001-930782
US 2003-703235


20040723
20060629
P 19960724
A2 19970723
A 19960724
A3 19970723
A3 19970723
A 19980128
A 19980128
A 19980128
A3 19990128
W 19990128
B1 20010816
A1 20031107

OTHER SOURCE(S): MARPAT 135:344507
IT 202579-74-6P 202579-75-7P 202579-76-8P
202579-77-9P 202579-85-9P 202579-86-0P
202579-89-3P 202579-91-7P 202579-93-9P
202579-94-0P 202579-95-1P 202579-96-2P
202580-25-4P 202580-26-5P 202580-27-6P
202580-28-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists)


RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-76-8 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-77-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-85-9 CAPLUS
CN Propanenitrile, 3-[(3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)propylamino]- (CA INDEX NAME)




RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-89-3 CAPLUS

CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-93-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 202579-94-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-95-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-96-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-25-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-26-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-27-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202580-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)



GI




AB The title compds. [I or II; A = N, CR; Z = N, CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, alkyl, alkenyl, etc.; R₁ = H, alkyl, alkenyl, etc.; R₂ = H, alkyl, alkenyl, etc.; R₃ = H, SH, OH, etc.; R₁₄ = C₁₋₁₀ alkyl, C₃₋₁₀ alkenyl, C₃₋₁₀ alkynyl, etc.], corticotropin releasing factor (CRF) antagonists (no data) which are useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-*a*]pyrazolo-1,3,5-triazin-4-one with POC₁₃ and N,N-dimethylaniline, followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-*a*]pyrazolo-1,3,5-triazine with 1,3-dimethoxy-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R₁ = Me; R₃ = NHCH(CH₂OMe)₂; Ar = 2,4-C₁₂C₆H₃].


REFERENCE COUNT: 103 THERE ARE 103 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

LS ANSWER 20 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:796238 CAPLUS
 DOCUMENT NUMBER: 135:339292
 TITLE: Combinations of corticotropin releasing factor
 antagonists and growth hormone secretagogues
 INVENTOR(S): Fossa, Anthony A.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 58 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| EP 1149583 | A2 | 20011031 | EP 2001-303033 | 20010330 |
| EP 1149583 | A3 | 20011114 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IB, SI, LT, LV, FI, RO | | | | |
| BR 2001001456 | A | 20011204 | BR 2001-1456 | 20010411 |
| MX 2001PA03855 | A | 20020604 | MX 2001-PA3855 | 20010411 |
| CA 2344089 | A1 | 20011013 | CA 2001-2344089 | 20010412 |
| US 20010041673 | A1 | 20011115 | US 2001-834477 | 20010413 |
| PRIORITY APPLN. INFO.: | | | US 2000-196698P | P 20000413 |
| OTHER SOURCE(S): MARPAT 135:339292 | | | | |
| IT 195054-99-0 202579-86-0 | | | | |
| RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| (combinations of corticotropin releasing factor antagonists and growth hormone secretagogues) | | | | |
| RN 195054-99-0 CAPLUS | | | | |
| CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME) | | | | |



RN 202579-86-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



AB This invention is directed to pharmaceutical compns. comprising corticotropin releasing factor antagonist and growth hormone or growth hormone secretagogues, prodrugs thereof, or pharmaceutically acceptable salts of said compds. or said prodrugs (Markush structures given). The invention is also directed to the use of such compns. in the treatment or prevention of osteoporosis and heart-related diseases (including congestive heart failure) in mammals, particularly humans (no data).

LS ANSWER 21 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:338070 CAPLUS

DOCUMENT NUMBER: 134:336224

TITLE: Use of corticotropin releasing factor (CRF) antagonists for treating syndrome X

INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|-------------|
| EP 1097709 | A2 | 20010509 | EP 2000-309441 | 20001026 |
| EP 1097709 | A3 | 20051221 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| AU 776724 | B2 | 20040916 | AU 2000-66695 | 20001024 |
| ZA 2000006008 | A | 20020426 | ZA 2000-6008 | 20001026 |
| US 6589947 | B1 | 20030708 | US 2000-696822 | 20001026 |
| CA 2325069 | A1 | 20010429 | CA 2000-2325069 | 20001027 |
| HU 2000004194 | A2 | 20011228 | HU 2000-4194 | 20001027 |
| HU 2000004194 | A3 | 20020328 | | |
| NZ 507825 | A | 20041126 | NZ 2000-507825 | 20001027 |
| US 20070117805 | A1 | 20070524 | US 2006-580996 | 20061013 |
| PRIORITY APPLN. INFO.: | | | US 1999-162340P | P 19991029 |
| | | | US 2000-559384 | A3 20000427 |
| | | | US 2002-80174 | A1 20020219 |
| | | | US 2003-721318 | A1 20031125 |

OTHER SOURCE(S): MARPAT 134:336224


IT 195054-99-0 202579-86-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)


RN 195054-99-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB Compns. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.

LS ANSWER 22 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:247337 CAPLUS
 DOCUMENT NUMBER: 134:280853
 TITLE: Preparation of amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as NPY receptor antagonists
 INVENTOR(S): Darrow, James W.; De Lombaert, Stephane; Blum, Charles; Tran, Jennifer; Giangordano, Mark; Griffith, David Andrew; Carpino, Philip Albert
 PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 2001023388 | A2 | 20010405 | WO 2000-US26885 | 20000929 |
| WO 2001023388 | A3 | 20011018 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2379633 | A1 | 20010405 | CA 2000-2379633 | 20000929 |
| CA 2379633 | C | 20060620 | | |
| EP 1218381 | A2 | 20020703 | EP 2000-967132 | 20000929 |
| EP 1218381 | B1 | 20061206 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| US 6476038 | B1 | 20021105 | US 2000-676972 | 20000929 |
| HU 2002003131 | A2 | 20030128 | HU 2002-3131 | 20000929 |
| HU 2002003131 | A3 | 20040628 | | |
| JP 2003510326 | T | 20030318 | JP 2001-526540 | 20000929 |
| AT 347553 | T | 20061215 | AT 2000-967132 | 20000929 |
| ES 2277855 | T3 | 20070801 | ES 2000-967132 | 20000929 |
| BG 106507 | A | 20021229 | BG 2002-106507 | 20020311 |
| NO 2002001357 | A | 20020523 | NO 2002-1357 | 20020319 |
| ZA 2002002517 | A | 20030328 | ZA 2002-2517 | 20020328 |
| JP 2007077144 | A | 20070329 | JP 2006-241067 | 20060906 |
| PRIORITY APPLN. INFO.: | | | US 1999-156868P | P 19990930 |
| | | | JP 2001-526540 | A3 20000929 |
| | | | WO 2000-US26885 | W 20000929 |

OTHER SOURCE(S): MARPAT 134:280853
 IT 332225-31-7P 332225-68-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as NPY receptor antagonists)
 RN 332225-31-7 CAPLUS
 CN 1,2-Ethanediamine, N-cyclohexyl-N'-(3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)-(9CI) (CA INDEX NAME)




RN 332225-68-0 CAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-(3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)- (9CI) (CA INDEX NAME)



GI




AB The title compds. [I; N, CR14; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; A = (un)substituted $(CH_2)_m$ (wherein m = 1-3); B = (un)substituted $(CH_2)_n$ (n = 0-3); R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl; R5, R6 = H, alkyl, cycloalkyl, etc.] that are selective modulators of NPY1 receptors, and are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension, were prepared E.g., a multi-step synthesis of the pyrazolo[1,5-a]pyrimidine II was described. The NPY1 receptor binding affinity for the compds. I, expressed as a K_i , ranges from 0.1 nM to 10 μ M. The compds. I are also useful as probes for the localization of NPY1 receptors and as stds. in assays for NPY1 receptor binding. Compds. I were also tested for CRF1 receptor binding affinity.

LS ANSWER 23 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:247336 CAPLUS
 DOCUMENT NUMBER: 134:280866
 TITLE: Preparation of certain alkylene diamine-substituted
 pyrazolo[1,5-a]-1,5-pyrimidines and
 pyrazolo[1,5-a]-1,3,5-triazines as selective
 modulators of NPY1 receptors
 INVENTOR(S): Darrow, James W.; De Lombaert, Stephane; Blum,
 Charles; Tran, Jennifer; Giangiordano, Mark; Griffith,
 David Andrew; Carpino, Philip Albert
 PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.; De Lombaert,
 Stephane
 SOURCE: PCT Int. Appl., 133 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|-------------|
| WO 2001023387 | A2 | 20010405 | WO 2000-US26887 | 20000929 |
| WO 2001023387 | A3 | 20020124 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2379585 | A1 | 20010405 | CA 2000-2379585 | 20000929 |
| CA 2379585 | C | 20060620 | | |
| US 6372743 | B1 | 20020416 | US 2000-676970 | 20000929 |
| EP 1218379 | A2 | 20020703 | EP 2000-967134 | 20000929 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| HU 2002002678 | A2 | 20021228 | HU 2002-2678 | 20000929 |
| HU 2002002678 | A3 | 20040628 | | |
| JP 2003510325 | T | 20030318 | JP 2001-526539 | 20000929 |
| US 20030069246 | A1 | 20030410 | US 2002-83245 | 20020225 |
| BG 106506 | A | 20021229 | BG 2002-106506 | 20020311 |
| NO 2002001356 | A | 20020523 | NO 2002-1356 | 20020319 |
| ZA 2002002519 | A | 20031128 | ZA 2002-2519 | 20020328 |
| PRIORITY APPLN. INFO.: | | | US 1999-156869P | P 19990930 |
| | | | US 2000-676970 | A1 20000929 |
| | | | WO 2000-US26887 | W 20000929 |

OTHER SOURCE(S): MARPAT 134:280866
 IT 332178-43-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)
 RN 332178-43-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-

dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)





IT 332178-33-3P 332178-41-3P 332178-42-4P
332178-44-6P 332178-45-7P 332178-46-8P
332178-47-9P 332178-48-0P 332178-49-1P
332178-50-4P 332178-51-5P 332178-52-6P
332178-53-7P 332178-54-8P 332178-55-9P
332178-56-0P 332178-57-1P 332178-59-3P
332178-60-6P 332178-61-7P 332178-62-8P
332178-63-9P 332178-64-0P 332178-66-2P
332178-68-4P 332178-69-5P 332178-76-4P
332178-79-7P 332178-85-5P 332178-86-6P
332178-87-7P 332178-88-8P 332178-89-9P
332178-90-2P 332178-91-3P 332178-92-4P
332178-94-6P 332178-95-7P 332178-97-9P
332178-99-1P 332179-00-7P 332179-01-8P
332179-05-2P 332179-24-5P 332179-25-6P
332179-26-7P 332179-27-8P 332179-28-9P
332179-29-0P 332179-30-3P 332179-31-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)


RN 332178-33-3 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-(4-ethoxy-3-methoxyphenyl)ethyl)-(9CI) (CA INDEX NAME)



RN 332178-41-3 CAPLUS
 CN Cyclohexanol, 4-[(2-[(3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]ethyl]amino]-, trans- (CA INDEX NAME)


Relative stereochemistry.



RN 332178-42-4 CAPLUS

CN Cyclohexanol, 4-[[2-[(3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]ethyl]amino]-, hydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332178-44-6 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-

(9CI) (CA INDEX NAME)



RN 332178-45-7 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-propoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 332178-46-8 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-propoxyphenyl)-2,5-

dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)-
(9CI) (CA INDEX NAME)




RN 332178-47-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-N-[(6-methyl-2-piperidinyl)methyl]- (CA INDEX NAME)



RN 332178-48-0 CAPLUS


CN 1-Butanol, 2-[(2-[(3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]ethyl)amino]- (CA INDEX NAME)



RN 332178-49-1 CAPLUS

CN 1,4-Cyclohexanediamine, N-[2-[(3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]ethyl]-N'-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

RN 332178-50-4 CAPLUS

CN 1,4-Cyclohexanediamine, N-[2-[(3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]ethyl]-N'-ethyl- (9CI) (CA

INDEX NAME)


PAGE 1-A




PAGE 2-A

RN 332178-51-5 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(4-(4-morpholinyl)cyclohexyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-52-6 CAPLUS

CN Cyclohexanol, 4-[{2-[{3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl}amino]ethyl}amino]- (CA INDEX NAME)




RN 332178-53-7 CAPLUS
 CN 1,2-Propanediol, 3-[2-[(3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)aminoethyl]amino]- (CA INDEX NAME)



RN 332178-54-8 CAPLUS
 CN 1,4-Cyclohexanediamine, N-[2-[(3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)aminoethyl]-N'-(2-methylpropyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-55-9 CAPLUS

CN Cyclohexanol, 4-[[2-[(3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)amino]-1-methylethyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-56-0 CAPLUS

CN Cyclohexanol, 2-[{2-[{3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl}amino]ethyl}amino]- (CA INDEX NAME)




RN 332178-57-1 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(4,4,4-trifluorobutyl)- (9CI)
 (CA INDEX NAME)

F₃C-(CH₂)₃-NH-CH₂-CH₂-NH




RN 332178-59-3 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2,2-trifluoroethyl)- (9CI)
 (CA INDEX NAME)




RN 332178-60-6 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-(trifluoromethyl)cyclohexyl)-(9CI) (CA INDEX NAME)




RN 332178-61-7 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(4-(trifluoromethyl)cyclohexyl)-(9CI) (CA INDEX NAME)




RN 332178-62-8 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2-difluoroethyl)- (9CI) (CA INDEX NAME)


F₂CH—CH₂—NH—CH₂—CH₂—NH

RN 332178-63-9 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-fluoro-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 332178-64-0 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-fluorocyclohexyl)- (9CI) (CA INDEX NAME)




RN 332178-66-2 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,4-dichloro-6-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 332178-68-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-al]pyrimidin-7-yl]-N'-(tetrahydro-2-methyl-3-furanyl)- (9CI) (CA INDEX NAME)




RN 332178-69-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-al]pyrimidin-7-yl]-N'-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 332178-76-4 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-al]pyrimidin-7-yl]-N'-(tetrahydro-2-methyl-3-furanyl)- (9CI) (CA INDEX NAME)




RN 332178-79-7 CAPLUS
 CN 1,2-Ethanediamine, N-3-cyclohexenyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-al]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 332178-85-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,4-dichloro-6-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(phenylmethyl)-4-piperidinyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-86-6 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(phenylmethyl)-4-piperidinyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-87-7 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-methyl-4-piperidinyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-88-8 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-4-piperidinyl)- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-89-9 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(1-methylethyl)-4-piperidinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-90-2 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2,2,6,6-tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332178-91-3 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-ethyl-3-piperidinyl)- (9CI)
(CA INDEX NAME)



RN 332178-92-4 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-4-piperidinyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 332178-94-6 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(3-pyridinylmethyl)-4-piperidinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 332178-95-7 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(4-pyridinylmethyl)-4-

piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 332178-97-9 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(2-pyridinylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332178-99-1 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-00-7 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(2-pyrimidinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-01-8 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1-(phenylmethyl)-4-piperidinyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-05-2 CAPLUS

CN 1,2-Propanediamine, N1-[3-(2,6-dichloro-4-ethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N2-[1-(2-pyrimidinyl)-4-piperidinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-24-5 CAPLUS

CN 4-Piperidinamine, 1-acetyl-N-[[[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 332179-25-6 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-(4-methoxyphenyl)ethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-26-7 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(3-ethoxy-4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 332179-27-8 CAPLUS
CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-[2-(4-ethoxy-3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 332179-28-9 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 332179-29-0 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-(2-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332179-30-3 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-(3-pyridinyl)ethyl)- (9CI)
(CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 332179-31-4 CAPLUS


CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-N'-(2-(4-pyridinyl)ethyl)- (9CI)
(CA INDEX NAME)



- IT 332179-74-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of certain alkylene diamine-substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines as selective modulators of NPY1 receptors)
 RN 332179-74-5 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; X = N, CR14; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl which optionally forms (un)substituted aminocarbocycle or aminoheterocycle with A and B, etc.; R2 and R6 with 2 N atoms to which they are bound, form (un)substituted aminoheterocycle; R2 and A form (un)substituted aminocarbocycle, aminoheterocycle; A, B = (un)substituted alkyl; A and B form (un)substituted carbocycle; B and R6 form (un)substituted aminocarbocycle; R3 = H, alkyl, cycloalkyl, etc.; R4 = (un)substituted aryl, heteroaryl; R5 = (un)substituted (cycloalkyl)alkyl, alkenyl, alkynyl, etc.; R6 = H, alkyl, cycloalkyl, etc.; R14 = H, alkyl, etc.] which are selective modulators of NPY1 receptors, and are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension, were prepared E.g., a multi-step synthesis of the pyrazolo[1,5-a]pyrimidine II, was described. The NPY1 binding affinity for the compds. I, expressed as a Ki value, ranges from 0.1 nM to 10 μ M. Compds. I are also useful as probes for the localization of NPY1 receptors and as stds. in assays for NPY1 receptor binding. Methods of using the compds. I in receptor localization studies are given.

LS ANSWER 24 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:185043 CAPLUS
 DOCUMENT NUMBER: 134:217215
 TITLE: Use of CRF antagonists and related compositions for
 modifying circadian rhythm and treatment of depression
 and other conditions
 INVENTOR(S): Chen, Yuhpyng Liang
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 29 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|---|---|
| EP 1082960 | A2 | 20010314 | EP 2000-307074 | 20000818 |
| EP 1082960 | A3 | 20020320 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO | | | | |
| US 6432989 | B1 | 20020813 | US 2000-587007 | 20000605 |
| EP 1449532 | A1 | 20040825 | EP 2004-12293 | 20000818 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY | | | | |
| JP 2001097889 | A | 20010410 | JP 2000-251836 | 20000823 |
| HU 2000003386 | A2 | 20010730 | HU 2000-3386 | 20000824 |
| HU 2000003386 | A3 | 20030828 | | |
| ZA 2000004362 | A | 20020225 | ZA 2000-4362 | 20000824 |
| CA 2316662 | A1 | 20010227 | CA 2000-2316662 | 20000825 |
| NZ 506562 | A | 20020927 | NZ 2000-506562 | 20000825 |
| AU 776077 | B2 | 20040826 | AU 2000-53644 | 20000825 |
| US 20020156089 | A1 | 20021024 | US 2002-161816 | 20020604 |
| US 20040082597 | A1 | 20040429 | US 2003-676201
US 1999-151183P
US 2000-587007
EP 2000-307074
US 2002-161816 | 20031001
P 19990827
A3 20000605
A3 20000818
A3 20020604 |

PRIORITY APPLN. INFO.:
 IT 195054-99-0 202579-86-0
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(CRF antagonists and related compns. for modifying circadian rhythm and
 treatment of depression and other conditions, and use with other
 agents)


RN 195054-99-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




AB A corticotropin releasing factor (CRF) antagonist is administered to treat disorders that can be treated by altering circadian rhythm, as well as depression (in which a second compound for treating depression is administered, the second compound having an onset of action that is delayed with respect to that of the CRF antagonist). Methods for treating cardiovascular diseases, migraine, non-migraine headaches, and emesis are also disclosed.

LS ANSWER 25 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:131201 CAPLUS
 DOCUMENT NUMBER: 134:178572
 TITLE: Preparation of azolo triazines and pyrimidines as corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis, Argyrios Georgios
 PATENT ASSIGNEE(S): Dupont Pharmaceuticals Co., USA
 SOURCE: U.S., 90 pp., Cont.-in-part of U. S. Ser. No. 899,242.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|------------|
| US 6191131 | B1 | 20010220 | US 1998-15002 | 19980128 |
| CA 2532925 | A1 | 19980129 | CA 1997-2532925 | 19970723 |
| US 6124289 | A | 20000926 | US 1997-899242 | 19970723 |
| EP 1908764 | A1 | 20080409 | EP 2007-15514 | 19970723 |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT,
SE, AL, LT, LV, RO, SI | | | | |
| ZA 9706603 | A | 19990125 | ZA 1997-6603 | 19970724 |
| US 6136809 | A | 20001024 | US 1998-14999 | 19980128 |
| LT 4680 | B | 20000725 | LT 1999-8 | 19990125 |
| CA 2314613 | A1 | 19990805 | CA 1999-2314613 | 19990128 |
| CA 2614603 | A1 | 19990805 | CA 1999-2614603 | 19990128 |
| WO 9938868 | A1 | 19990805 | WO 1999-US1824 | 19990128 |
| W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL,
RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE | | | | |
| AU 9924787 | A | 19990816 | AU 1999-24787 | 19990128 |
| AU 748818 | B2 | 20020613 | | |
| EP 1049699 | A1 | 20001108 | EP 1999-904382 | 19990128 |
| EP 1049699 | B1 | 20040421 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO | | | | |
| BR 9908206 | A | 20001205 | BR 1999-8206 | 19990128 |
| JP 2002501922 | T | 20020122 | JP 2000-529335 | 19990128 |
| NZ 505079 | A | 20030829 | NZ 1999-505079 | 19990128 |
| EP 1344779 | A1 | 20030917 | EP 2003-75887 | 19990128 |
| EP 1344779 | B1 | 20050810 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
SI, LT, LV, FI, RO | | | | |
| AT 264860 | T | 20040515 | AT 1999-904382 | 19990128 |
| PT 1049699 | T | 20040831 | PT 1999-904382 | 19990128 |
| CN 1542010 | A | 20041103 | CN 2003-10122546 | 19990128 |
| ES 2218991 | T3 | 20041116 | ES 1999-904382 | 19990128 |
| SG 111076 | A1 | 20050530 | SG 2002-4556 | 19990128 |
| AT 301657 | T | 20050815 | AT 2003-75887 | 19990128 |
| PT 1344779 | T | 20051031 | PT 2003-75887 | 19990128 |
| ES 2247478 | T3 | 20060301 | ES 2003-75887 | 19990128 |
| TW 520372 | B | 20030211 | TW 1999-88102636 | 19990223 |
| US 6358950 | B1 | 20020319 | US 2000-696759 | 200001026 |
| HK 1060348 | A1 | 20051021 | HK 2004-101985 | 20040317 |
| JP 2005097257 | A | 20050414 | JP 2004-216483 | 20040723 |
| PRIORITY APPLN. INFO.: | | | US 1996-23290P | P 19960724 |

| | | | |
|----|--------------|----|----------|
| US | 1997-899242 | A2 | 19970723 |
| US | 1996-686047 | A | 19960724 |
| CA | 1997-2259583 | A3 | 19970723 |
| EP | 1997-936222 | A3 | 19970723 |
| JP | 1998-507233 | A3 | 19970723 |
| US | 1998-14734 | A | 19980128 |
| US | 1998-15001 | A | 19980128 |
| US | 1998-15002 | A | 19980128 |
| CA | 1999-2314613 | A3 | 19990128 |
| EP | 1999-904382 | A3 | 19990128 |
| WO | 1999-US1824 | W | 19990128 |


OTHER SOURCE(S): MARPAT 134:178572
 IT 202579-74-6P 202579-75-7P 202579-76-8P
 202579-77-9P 202579-85-9P 202579-86-0P
 202579-89-3P 202579-91-7P 202579-93-9P
 202579-94-0P 202579-95-1P 202579-96-2P
 202580-25-4P 202580-26-5P 202580-27-6P
 202580-28-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolo-fused triazines and pyrimidines as CRF antagonists)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202579-75-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-76-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202579-77-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-85-9 CAPLUS

CN Propanenitrile, 3-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino- (CA INDEX NAME)




RN 202579-86-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-89-3 CAPLUS
 CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202579-91-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-(1-(methoxymethyl)propyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-93-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 202579-94-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-95-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-96-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-25-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-26-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-27-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202580-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, alk(en/yn)yl, halo, etc.; R₁, R₂ = H, alk(en/yn)yl, halo, etc.; R₃ = H, SH, aryl, etc.; R₁₄ = (un)substituted alk(en/yn)yl, cycloalkyl(alkyl)], useful in treating CRF-related disorders, particularly anxiety, depression, and other psychiatric, neurol. disorders as well as treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. For instance, 5-amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole was cyclized with Et acetoacetate in AcOH to give 42% 7-hydroxy-2,5-dimethyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine. The latter was treated with POCl₃ and PhNET₂ to give the 7-chloro analog (84%), which reacted with 3-pentylamine to give 60% title compound I [A = CH; R₁ = Me; R₃ = NHCH₂T₂; Z = CMe; Ar = 2-Cl-4-MeC₆H₃]. The compds. I are effective at 0.002-200 mg/kg/day.

REFERENCE COUNT: 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 26 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:307132 CAPLUS
 DOCUMENT NUMBER: 132:321873
 TITLE: Azolo triazines and pyrimidines useful as corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): Gilligan, Paul; Chorvat, Robert; Arvanitis, Argyrios Georgios
 PATENT ASSIGNEE(S): DuPont Pharmaceuticals Co., USA
 SOURCE: U.S., 86 pp., Cont.-in-part of U.S. Ser. No. 899,242.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|-------------|
| US 6060478 | A | 20000509 | US 1998-15001 | 19980128 |
| CA 2532925 | A1 | 19980129 | CA 1997-2532925 | 19970723 |
| US 6124289 | A | 20000926 | US 1997-899242 | 19970723 |
| EP 1908764 | A1 | 20080409 | EP 2007-15514 | 19970723 |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE, AL, LT, LV, RO, SI | | | | |
| ZA 9706603 | A | 19990125 | ZA 1997-6603 | 19970724 |
| US 6136809 | A | 20001024 | US 1998-14999 | 19980128 |
| LT 4680 | B | 20000725 | LT 1999-8 | 19990125 |
| CA 2314613 | A1 | 19990805 | CA 1999-2314613 | 19990128 |
| CA 2614603 | A1 | 19990805 | CA 1999-2614603 | 19990128 |
| WO 9938868 | A1 | 19990805 | WO 1999-US1824 | 19990128 |
| W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| AU 9924787 | A | 19990816 | AU 1999-24787 | 19990128 |
| AU 748818 | B2 | 20020613 | | |
| EP 1049699 | A1 | 20001108 | EP 1999-904382 | 19990128 |
| EP 1049699 | B1 | 20040421 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO | | | | |
| BR 9908206 | A | 20001205 | BR 1999-8206 | 19990128 |
| JP 2002501922 | T | 20020122 | JP 2000-529335 | 19990128 |
| NZ 505079 | A | 20030829 | NZ 1999-505079 | 19990128 |
| EP 1344779 | A1 | 20030917 | EP 2003-75887 | 19990128 |
| EP 1344779 | B1 | 20050810 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO | | | | |
| AT 264860 | T | 20040515 | AT 1999-904382 | 19990128 |
| PT 1049699 | T | 20040831 | PT 1999-904382 | 19990128 |
| CN 1542010 | A | 20041103 | CN 2003-10122546 | 19990128 |
| ES 2218991 | T3 | 20041116 | ES 1999-904382 | 19990128 |
| SG 111076 | A1 | 20050530 | SG 2002-4556 | 19990128 |
| AT 301657 | T | 20050815 | AT 2003-75887 | 19990128 |
| PT 1344779 | T | 20051031 | PT 2003-75887 | 19990128 |
| ES 2247478 | T3 | 20060301 | ES 2003-75887 | 19990128 |
| TW 520372 | B | 20030211 | TW 1999-88102636 | 19990223 |
| HK 1060348 | A1 | 20051021 | HK 2004-101985 | 20040317 |
| JP 2005097257 | A | 20050414 | JP 2004-216483 | 20040723 |
| PRIORITY APPLN. INFO.: | | | US 1996-23290P | P 19960724 |
| | | | US 1997-899242 | A2 19970723 |

| | | | |
|----|--------------|----|----------|
| US | 1996-686047 | A | 19960724 |
| CA | 1997-2259583 | A3 | 19970723 |
| EP | 1997-936222 | A3 | 19970723 |
| JP | 1998-507233 | A3 | 19970723 |
| US | 1998-14734 | A | 19980128 |
| US | 1998-15001 | A | 19980128 |
| US | 1998-15002 | A | 19980128 |
| CA | 1999-2314613 | A3 | 19990128 |
| EP | 1999-904382 | A3 | 19990128 |
| WO | 1999-US1824 | W | 19990128 |

OTHER SOURCE(S):

MARPAT 132:321873

| IT | 202579-74-6P | 202579-75-7P | 202579-76-8P |
|----|--------------|--------------|--------------|
| | 202579-77-9P | 202579-85-9P | 202579-86-0P |
| | 202579-88-3P | 202579-91-7P | 202579-93-9P |
| | 202579-94-0P | 202579-95-1P | 202579-96-2P |
| | 202580-25-4P | 202580-26-5P | 202580-27-6P |
| | 202580-28-7P | 202580-58-3P | 234777-26-5P |
| | 234777-27-6D | 234777-36-7P | 234777-37-8P |
| | 234777-42-5P | 234777-44-7P | 234777-46-9P |
| | 234777-47-0P | 234777-48-1P | 234777-49-2P |
| | 234777-51-6D | 234777-52-7P | 234778-37-1P |
| | 234778-38-2P | 234778-39-3P | 234778-40-6P |
| | 234778-41-7P | 234778-42-8P | 234778-43-9P |
| | 234778-44-0P | 234778-45-1P | 234778-46-2P |
| | 234778-47-3P | 234778-48-4P | 234778-49-5P |
| | 234778-50-8P | 234778-51-9P | 234778-52-0P |
| | 262222-60-3P | | |


26/253-35^F
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of azolo-fused triazines and pyrimidines as

CRF

antagonists)


RN 202579-74-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-75-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-76-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-77-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[(1S)-3-methoxy-1-(methoxymethyl)propyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 202579-85-9 CAPLUS
 CN Propanenitrile, 3-[(3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)propylamino]- (CA INDEX NAME)




RN 202579-86-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-89-3 CAPLUS
 CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202579-91-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-93-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 202579-94-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-95-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-96-2 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-25-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-26-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-27-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-28-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202580-58-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 234777-26-5 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-27-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-36-7 CAPLUS
 CN Propanenitrile, 3-[3-(4-methoxy-2-methylphenyl)-2,5,6-trimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino- (CA INDEX NAME)




RN 234777-37-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-42-5 CAPLUS
CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5,6-trimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 234777-44-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)



RN 234777-46-9 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-47-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-48-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-49-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-51-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-52-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-37-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-propyl- (CA INDEX NAME)



RN 234778-38-2 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-39-3 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-40-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-41-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl-N-propyl- (CA INDEX NAME)




RN 234778-42-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-43-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (CA INDEX NAME)




RN 234778-44-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-45-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-2,5,6-trimethyl-N-propyl- (CA INDEX NAME)




RN 234778-46-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-47-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-48-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-49-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl-N-propyl- (CA INDEX NAME)




RN 234778-50-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-51-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (CA INDEX NAME)




RN 234778-52-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)





RN 267233-60-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




GI




AB Corticotropin releasing factor (CRF) antagonists (no data) of formulas I and II are disclosed [wherein A = N or CR; Z = N or CR₂; Ar = (un)substituted Ph, naphthyl, pyridyl, pyrimidinyl, indanyl, tetralinyl, addnl. selected heterocycles; R = H, alk(en/yn)yl, cycloalkyl(alkyl), halo, cyano, haloalkyl; R₁, R₂ = H, groups listed for R, NH₂ or derivs., OH or derivs., SH or derivs., addnl. substituted alkyls; R³ = H, OH or derivs., SH or derivs., acyl, CO₂H or esters, NH₂ or derivs., aryl, heteroaryl, alk(en/yn)yl, etc.; R⁴ = (un)substituted alk(en/yn)yl or cycloalkyl(alkyl)]. The compds. are of use in the treatment of CRF-related disorders, particularly anxiety and depression, as well as other psychiatric, neurol., immunol., cardiovascular, and psychopathol. disorders. For instance, 5-amino-4-(2-chloro-4-methylphenyl)-3-methylpyrazole was cyclized with Et acetoacetate in AcOH to give 42% 7-hydroxy-5-methyl-3-(2-chloro-4-methylphenyl)pyrazolo[1,5-a]pyrimidine. The latter was treated with POCl₃ and PhNEt₂ to give the 7-chloro analog (84%), which reacted with 3-pentylamine to give 60% title compound III.

REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 27 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:125866 CAPLUS
 DOCUMENT NUMBER: 132:231516
 TITLE: The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist
 AUTHOR(S): Gilligan, Paul J.; Baldauf, Caryn; Cocuzza, Anthony; Chidester, Dennis; Zaczek, Robert; Fitzgerald, Lawrence W.; McElroy, John; Smith, Mark A.; Shen, H.-S. L.; Saye, Jo Anne; Christ, David; Trainor, George; Robertson, David W.; Hartig, Paul
 CORPORATE SOURCE: Chemical and Physical Sciences Department, Experimental Station, DuPont Pharmaceuticals Co., Wilmington, DE, 10880-0500, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(1), 181-189
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 202579-74-6P
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (structure-activity relationships of pyrazolo-[1,5-a]-pyrimidines as human CRF1 antagonists leading to discovery of anxiolytic DMP904)
 RN 202579-74-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




IT 202579-75-7 202579-85-9 202579-86-0
 202579-89-3 202579-91-7 202579-93-9
 202579-94-0 202579-95-1 202579-96-2
 202580-25-4 202580-27-6 202580-28-7
 262297-99-4 262298-00-0 262298-01-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (structure-activity relationships of pyrazolo-[1,5-a]-pyrimidines as human CRF1 antagonists leading to discovery of anxiolytic DMP904)
 RN 202579-75-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-85-9 CAPLUS

CN Propanenitrile, 3-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino- (CA INDEX NAME)




RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-89-3 CAPLUS

CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino- (CA INDEX NAME)




RN 202579-91-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-[1-(methoxymethyl)propyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-93-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 202579-94-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-95-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-96-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-25-4 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-27-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)



RN 262297-99-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 262298-00-0 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)



RN 262298-01-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)



AB Structure-activity relationship studies led to the discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine (compound 11-31, DMP904), whose pharmacol. profile strongly supports the hypothesis that hCRF1 antagonists may be potent anxiolytic drugs. Compound 11-31 (hCRF1 Ki = 1.0 ± 0.2 nM (n = 8)) was a potent antagonist of hCRF1-coupled adenylyl cyclase activity in HEK293 cells (IC50 = 10.0 ± 0.01 nM vs. 10 nM r/hCRF, n = 8); α -helical CRF(9-41) had weaker potency (IC50 = 286 ± 63 nM, n = 3). Analog 11-31 had good oral activity in the rat situational anxiety test; the min. ED for 11-31 was 0.3 mg/kg, orally. Maximal efficacy (approx. 57% reduction in latency time in the dark compartment) was observed at this dose. Chlordiazepoxide caused a 72% reduction in latency at 20 mg/kg, orally. CP154526-1 (30 mg/kg, orally) was inactive in this test. Compound 11-31 did not inhibit open-field locomotor activity at 10, 30, and 100 mg/kg, orally in rats. In beagle dogs, this compound (5 mg/kg, i.v., orally) afforded good plasma levels. The key i.v. pharmacokinetic parameters were t1/2, CL and Vd.ss values equal to 46.4 ± 7.6 h, 0.49 ± 0.08 L/kg/h and 23.0 ± 4.2 L/kg, resp. After oral dosing, the mean Cmax, Tmax, t1/2 and bioavailability values were equal to 1260 ± 290 nM, 0.75 ± 0.25 h, 45.1 ± 10.2 h and 33.1%, resp. The overall rat behavioral profile of this compound suggests that it may be an anxiolytic drug with a low motor side effect liability.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 28 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:495296 CAPLUS
 DOCUMENT NUMBER: 131:144616
 TITLE: Preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists
 INVENTOR(S): He, Liqi; Gilligan, Paul; Chorvat, Robert; Arvanitis, Argyrios Georgios
 PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
 SOURCE: PCT Int. Appl., 245 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------------|-----------------|----------|
| WO 9938868 | A1 | 19990805 | WO 1999-US1824 | 19990128 |
| W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| US 6060478 | A | 20000509 | US 1998-15001 | 19980128 |
| US 6191131 | B1 | 20010220 | US 1998-15002 | 19980128 |
| US 6313124 | B1 | 20011106 | US 1998-14734 | 19980128 |
| CA 2314613 | A1 | 19990805 | CA 1999-2314613 | 19990128 |
| AU 9924787 | A | 19990816 | AU 1999-24787 | 19990128 |
| AU 748818 | B2 | 20020613 | | |
| EP 1049699 | A1 | 20001108 | EP 1999-904382 | 19990128 |
| EP 1049699 | B1 | 20040421 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO | | | | |
| BR 9908206 | A | 20001205 | BR 1999-8206 | 19990128 |
| JP 2002051922 | T | 20020122 | JP 2000-529335 | 19990128 |
| NZ 505079 | A | 20030829 | NZ 1999-505079 | 19990128 |
| AT 264860 | T | 20040515 | AT 1999-904382 | 19990128 |
| ZA 9900843 | A | 20000802 | ZA 1999-843 | 19990203 |
| MX 2000PA06495 | A | 20011011 | MX 2000-PA6495 | 20000629 |
| AU 2002300983 | A1 | 20030220 | AU 2002-300983 | 20020911 |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 1998-14734 | A | 19980128 |
| | | US 1998-15001 | A | 19980128 |
| | | US 1998-15002 | A | 19980128 |
| | | US 1996-23290P | P | 19960724 |
| | | US 1997-899242 | A2 | 19970723 |
| | | AU 1999-24787 | A3 | 19990128 |
| | | WO 1999-US1824 | W | 19990128 |


IT 202579-86-0P 234777-26-5P 234777-27-6P
 234777-36-7P 234777-37-8P 234777-42-5P
 234777-44-7P 234777-46-9P 234777-47-0P
 234777-48-1P 234777-49-2P 234777-51-6P
 234777-52-7P 234778-37-1P 234778-38-2P
 234778-39-3P 234778-40-6P 234778-41-7P
 234778-42-8P 234778-43-9P 234778-44-0P
 234778-45-1P 234778-46-2P 234778-47-3P
 234778-48-4P 234778-49-5P 234778-50-8P
 234778-51-9P 234778-52-0P 234778-53-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azolotriazines and -pyrimidines as CRF antagonists for treatment of anxiety, depression, and other psychiatric, neuroleptic disorders)


RN 202579-86-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 234777-26-5 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-27-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-36-7 CAPLUS


CN Propanenitrile, 3-[(3-(4-methoxy-2-methylphenyl)-2,5,6-trimethylpyrazolo[1,5-a]pyrimidin-7-yl)propylamino]- (CA INDEX NAME)




RN 234777-37-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)



RN 234777-42-5 CAPLUS
 CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5,6-trimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 234777-44-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-46-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-47-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-48-1 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-49-2 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-51-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5,6-trimethyl- (CA INDEX NAME)




RN 234777-52-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-37-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-propyl- (CA INDEX NAME)




RN 234778-38-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)



RN 234778-39-3 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-40-6 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-41-7 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl-N-propyl- (CA INDEX NAME)




RN 234778-42-8 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2-methylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-43-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl-N-(1-methylpropyl)- (CA INDEX NAME)




RN 234778-44-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2-methylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)



RN 234778-45-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-46-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-2,5,6-trimethyl- (CA INDEX NAME)




RN 234778-47-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N-(2-methoxyethyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-48-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-ethyl-3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl- (CA INDEX NAME)




RN 234778-49-5 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-N,2,5,6-tetramethyl-N-propyl- (CA INDEX NAME)




RN 234778-50-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(4-methoxy-2,5-dimethylphenyl)-
 N,2,5,6-tetramethyl- (CA INDEX NAME)



RN 234778-51-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,5-dimethylphenyl)-2,5,6-
 trimethyl-N-(1-methylpropyl)- (CA INDEX NAME)




RN 234778-52-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclobutyl-3-(4-methoxy-2,5-
 dimethylphenyl)-2,5,6-trimethyl- (CA INDEX NAME)





RN 234778-53-1 CAPLUS

CN Butanenitrile, 4-[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]propylamino- (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR2; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, C1-4 alkyl, C2-4 alkenyl, etc.; R1 = H, C1-4 alkyl, C2-4 alkenyl, etc.; R2 = H, C1-4 alkyl, C2-4 alkenyl, etc.; R3 = H, SH, OH, etc.; R14 = C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists (no data) which are useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-a]pyrazolo-1,3,5-triazin-4-one with POC13 and N,N-dimethylaniline, followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine with 1,3-dimethoxy-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R1 = Me; R3 = NHCH(CH2OMe)2; Ar = 2,4-C12C6H3].
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1998:87733 CAPLUS

DOCUMENT NUMBER: 128:154103

TITLE: Preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists

INVENTOR(S): Arvanitis, Argyrios Georgious; Chorvat, Robert John
PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Co., USASOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|-----------------|------------------|----------|
| WO 9803510 | A1 | 19980129 | WO 1997-US13072 | 19970723 |
| W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT,
LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN
RN: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| CA 2259583 | A1 | 19980129 | CA 1997-2259583 | 19970723 |
| CA 2532925 | A1 | 19980129 | CA 1997-2532925 | 19970723 |
| AU 9738942 | A | 19980210 | AU 1997-38942 | 19970723 |
| AU 747708 | B2 | 20020523 | | |
| EP 915880 | A1 | 19990519 | EP 1997-936222 | 19970723 |
| EP 915880 | B1 | 20071010 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| CN 1225637 | A | 19990811 | CN 1997-196525 | 19970723 |
| CN 1104432 | B | 20030402 | | |
| BR 9710544 | A | 19990817 | BR 1997-10544 | 19970723 |
| US 6124289 | A | 20000926 | US 1997-899242 | 19970723 |
| HU 2001002187 | A2 | 20011128 | HU 2001-2187 | 19970723 |
| HU 2001002187 | A3 | 20021228 | | |
| JP 2002513382 | T | 20020508 | JP 1998-507233 | 19970723 |
| EE 4316 | B1 | 20040615 | EE 1999-19 | 19970723 |
| RO 121272 | B1 | 20070228 | RO 1999-78 | 19970723 |
| AT 375344 | T | 20071015 | AT 1997-936222 | 19970723 |
| PL 195762 | B1 | 20071031 | PL 1997-331523 | 19970723 |
| ES 2294800 | T3 | 20080401 | ES 1997-936222 | 19970723 |
| EP 1908764 | A1 | 20080409 | EP 2007-15514 | 19970723 |
| R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT,
SE, AL, LT, LV, RO, SI | | | | |
| ZA 9706603 | A | 19990125 | ZA 1997-6603 | 19970724 |
| TW 542827 | B | 20030721 | TW 1997-86110640 | 19970725 |
| TW 238164 | B | 20050821 | TW 2003-92105694 | 19970725 |
| MX 9900633 | A | 20020131 | MX 1999-633 | 19990115 |
| LV 12292 | B | 19991120 | LV 1999-13 | 19990120 |
| NO 9900264 | A | 19990310 | NO 1999-264 | 19990121 |
| NO 315610 | B1 | 20030929 | | |
| LT 4680 | B | 20000725 | LT 1999-8 | 19990125 |
| CN 1327793 | A | 20011226 | CN 2001-120849 | 20010530 |
| AU 773039 | B2 | 20040513 | AU 2002-23236 | 20020312 |
| CN 1388126 | A | 20030101 | CN 2002-118589 | 20020425 |
| JP 2005097257 | A | 20050414 | JP 2004-216483 | 20040723 |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 1996-23290P | P 19960724 | |
| | | US 1996-686047 | A 19960724 | |
| | | US 1997-899242 | A 19970723 | |
| | | AU 1997-38942 | A3 19970723 | |
| | | CA 1997-2259583 | A3 19970723 | |

EP 1997-936222 A3 19970723
 JP 1998-507233 A3 19970723
 WO 1997-US13072 W 19970723


OTHER SOURCE(S): MARPAT 128:154103

IT 202579-74-6P 202579-75-7P 202579-76-8P
 202579-77-9P 202579-85-9P 202579-86-0P
 202579-89-3P 202579-91-7P 202579-93-9P
 202579-94-0P 202579-95-1P 202579-96-2P
 202580-25-4P 202580-26-5P 202580-27-6P
 202580-28-7P 202580-43-6P 202580-46-9P
 202580-48-1P 202580-50-5P 202580-58-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of azolotriazines and -pyrimidines as corticotropin releasing factor (CRF) antagonists)

RN 202579-74-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202579-75-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[2-methoxy-1-(methoxymethyl)ethyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-76-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-bis(2-methoxyethyl)-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202579-77-9 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[{(1S)-3-methoxy-1-(methoxymethyl)propyl}-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 202579-85-9 CAPLUS

CN Propanenitrile, 3-[(3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl)propylamino]- (CA INDEX NAME)




RN 202579-86-0 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-89-3 CAPLUS
 CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202579-91-7 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-N-(1-(methoxymethyl)propyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-93-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N,N-diethyl-2,5-dimethyl- (CA INDEX NAME)




RN 202579-94-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-chloro-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202579-95-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202579-96-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-25-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4,5-dimethoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-26-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5-dimethyl- (CA INDEX NAME)



RN 202580-27-6 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-28-7 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2-bromo-4-methoxyphenyl)-N-[2-methoxy-1-(methoxymethyl)ethyl]-2,5-dimethyl- (CA INDEX NAME)




RN 202580-43-6 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-3-(4-methoxy-2,3-dimethylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-46-9 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxy-2,3-dimethylphenyl)-N,N-bis(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-48-1 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(1-ethylpropyl)-3-(4-methoxy-2,3-dimethylphenyl)-2,5-dimethyl- (CA INDEX NAME)




RN 202580-50-5 CAPLUS

CN Propanenitrile, 3-[cyclopropyl[3-(4-methoxy-2,3-dimethylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]amino]- (CA INDEX NAME)




RN 202580-58-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-[1-(methoxymethyl)butyl]-3-(4-methoxy-2-methylphenyl)-2,5-dimethyl- (CA INDEX NAME)



GI



AB The title compds. [I or II; A = N, CR; Z = N, CR2; Ar = (un)substituted Ph, naphthyl, pyridyl, etc.; R = H, C1-4 alkyl, C2-4 alkenyl, etc.; R1 = H, C1-4 alkyl, C2-4 alkenyl, etc.; R2 = H, C1-4 alkyl, C2-4 alkenyl, etc.; R3 = H, SH, OH, etc.; R14 = C1-10 alkyl, C3-10 alkenyl, C3-10 alkynyl, etc.], corticotropin releasing factor (CRF) antagonists useful in treating anxiety, depression, and other psychiatric, neurol. disorders as well as in treatment of immunol., cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathol. disturbance and stress, were prepared and formulated. Thus, treatment of 2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-alpyrazolo-1,3,5-triazin-4-one with POC13 and N,N-dimethylaniline followed by reaction of the resulting 4-chloro-2,7-dimethyl-8-(2,4-dimethylphenyl)[1,5-alpyrazolo-1,3,5-triazine with 1,3-dimethoxypropyl-2-aminopropane in EtOH afforded I [A = N; Z = C(Me); R1 = Me; R3 = NHCH(CH₂OCH₃)₂; Ar = 2,4-C₁₂CGH₃].

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:542450 CAPLUS
DOCUMENT NUMBER: 127:220669

TITLE: Pyrazolopyrimidines as CRF receptor antagonists
INVENTOR(S): Chen, Chen; Webb, Thomas R.; McCarthy, James R.;
Moran, Terence J.; Wilcoxen, Keith M.

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.; Neurocrine
Biosciences, Inc.

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|--|------------------|-------------|
| WO 9729109 | A1 | 19970814 | WO 1997-EP459 | 19970130 |
| W: AL, AM, AU,
JE, KG, KR,
RO, SG, SI,
RW: KE, LS, MW,
IE, IT, LU,
MR, NE, SN, | BA, BB, BG, BR,
LC, LK, LR, LT,
SK, TR, TT,
SD, SZ, UG,
MC, NL, PT,
TD, TG | CA, CN, CU, CZ,
LV, MD, MG,
US, UZ,
AT, BE, CH,
SE, BF, BJ,
EE, GE, KZ,
FI, FR, GB,
CG, CI, CM,
NO, NZ, PL,
BY, TZ, TM,
ES, FI, FR,
GA, GN, ML, | | |
| CA 2233285 | A1 | 19970814 | CA 1997-2233285 | 19970130 |
| CA 2233285 | C | 20060704 | | |
| AU 9715991 | A | 19970828 | AU 1997-15991 | 19970130 |
| AU 713673 | B2 | 19991209 | | |
| EP 880523 | A1 | 19981202 | EP 1997-902295 | 19970130 |
| EP 880523 | B1 | 20060816 | | |
| R: AT, BE, CH,
SI, LT, LV,
FI | DE, DK, ES,
SI, LT, LV,
FI | FR, GB, GR,
IT, LI, LU,
NL, SE, PT,
IE, | | |
| CN 1205009 | A | 19990113 | CN 1997-191382 | 19970130 |
| CN 1090189 | B | 20020904 | | |
| HU 9900575 | A2 | 19990628 | HU 1999-575 | 19970130 |
| HU 9900575 | A3 | 20011128 | | |
| BR 9707391 | A | 19990720 | BR 1997-7391 | 19970130 |
| NZ 330119 | A | 20000228 | NZ 1997-330119 | 19970130 |
| JP 20000503661 | T | 20000328 | JP 1997-528123 | 19970130 |
| JP 3356291 | B2 | 20021216 | | |
| JP 2002121194 | A | 20020423 | JP 2001-265611 | 19970130 |
| EE 4282 | B1 | 20040415 | EE 1998-124 | 19970130 |
| PL 191271 | B1 | 20060428 | PL 1997-327284 | 19970130 |
| AT 336495 | T | 20060915 | AT 1997-902295 | 19970130 |
| ES 2168237 | T3 | 20070401 | ES 1997-902295 | 19970130 |
| IN 1998CA00198 | A | 20050311 | IN 1998-CA198 | 19970203 |
| TW 449599 | B | 20010811 | TW 1997-86101373 | 19970205 |
| ZA 9700989 | A | 19980806 | ZA 1997-989 | 19970206 |
| NO 9801357 | A | 19980803 | NO 1998-1357 | 19980325 |
| NO 310292 | B1 | 20010618 | | |
| US 20030125341 | A1 | 20030703 | US 1999-117717 | 19990302 |
| US 6664261 | B2 | 20031216 | | |
| US 20040127483 | A1 | 20040701 | US 2003-665740 | 20030919 |
| US 7074797 | B2 | 20060711 | | |
| US 20060270659 | A1 | 20061130 | US 2006-413610 | 20060428 |
| PRIORITY APPLN. INFO.: | | | US 1996-11279P | P 19960207 |
| | | | US 1996-27688P | P 19961008 |
| | | | JP 1997-528123 | A3 19970130 |
| | | | WO 1997-EP459 | W 19970130 |

US 1999-117717
US 2003-665740


A1 19990302
A1 20030919

OTHER SOURCE(S): MARPAT 127:220669
IT 195054-99-0P 195055-34-6P 195055-35-7P
195055-36-8P 195055-37-9P 195055-38-0P
195055-39-1P 195055-79-9P 195055-80-2P
195055-81-3P 195055-82-4P 195055-83-5P
195055-85-7P 195055-86-8P 195055-87-9P
195055-88-0P 195055-89-1P 195055-90-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyrazolopyrimidines as CRF receptor antagonists)

RN 195054-99-0 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)


MeO-CH₂-CH₂



RN 195055-34-6 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dimethoxyphenyl)-5-methyl-N-propyl- (CA INDEX NAME)

CH₂
N-Pr-n




RN 195055-35-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 5-methyl-N,N-dipropyl-3-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 195055-36-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(2-methoxyethyl)-5-methyl-N-propyl-3-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 195055-37-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-5-methyl-N-propyl-3-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 195055-38-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-N-ethyl-5-methyl-3-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)




RN 195055-39-1 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl-3-(2,4,6-trimethoxyphenyl)- (CA INDEX NAME)



RN 195055-79-9 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 195055-80-2 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)




RN 195055-81-3 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-cyclopropyl-3-(2,4-dimethoxyphenyl)-5-methyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 195055-82-4 CAPLUS

CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl- (CA INDEX NAME)




RN 195055-83-5 CAPLUS

CN Ethanol, 2-[{3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl}propylamino]- (CA INDEX NAME)




RN 195055-85-7 CAPLUS


CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 195055-86-8 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-butyl-3-(2,4-dimethoxyphenyl)-N-ethyl-2,5-dimethyl- (CA INDEX NAME)




RN 195055-87-9 CAPLUS
 CN 2-Propanol, 1-[{3-(2,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl}propylamino]- (CA INDEX NAME)




RN 195055-88-0 CAPLUS
 CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(4-methoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)




RN 195055-89-1 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, 3-(3-methoxyphenyl)-2,5-dimethyl-N,N-dipropyl- (CA INDEX NAME)



RN 195055-90-4 CAPLUS
CN Pyrazolo[1,5-a]pyrimidin-7-amine, N-(cyclopropylmethyl)-3-(3-methoxyphenyl)-2,5-dimethyl-N-propyl- (CA INDEX NAME)



GI



AB Title compds. I [R = (un)substituted Ph, pyridyl; R1 = substituted NH₂, (un)substituted alkoxy; R2 = alkyl, alkoxy, alkylthio; R3 = H, alkyl, alkylsulfonyl, alkylsulfoxy, alkylthiol] having CRF receptor antagonistic properties, were prepared. Thus, I [R = 2,4-C₁₂C₆H₃, R1 = N-propyl-N-cyclopropylmethylamino, R2 = Me, R3 = H, II] was obtained by treating 3-amino-4-(2,4-dichlorophenyl)pyrazole with MeCOCH₂CO₂Et, chlorinating I [R = 2,4-C₁₂C₆H₃, R1 = OH, R2 = Me, R3 = H] and aminating I [R1 = Cl]. II had a Ki for CRF receptor inhibition of <250 nM.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| FULL ESTIMATED COST | 170.70 | 349.73 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -24.00 | -24.00 |

STN INTERNATIONAL LOGOFF AT 16:42:34 ON 13 APR 2008